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CHAPTER 1 BASICS OF PROTON THERAPY 
1.1. Introduction 
The use of proton for radiation therapy was first proposed by Dr. Robert Wilson 
in his work in 1946 (1), when he postulated that the Bragg peak formed by hadrons 
could be used to deposit maximum energy inside the tumor. The first treatments with 
proton therapy were performed at Berkeley Lab in 1954 (2) using the 184 inch cyclotron 
as a source of protons to treat pituitary gland tumors. Proton therapy was also used to 
treat pituitary gland treatments in 1957 at Uppsala, Sweden (3) and in 1961 at Harvard 
Cyclotron Laboratory (4).  Proton therapy was limited to major research labs until 1990, 
when the first hospital based facility was opened at Loma Linda University (5) after two 
decades of development and collaboration with Fermi National Accelerator Laboratory. 
From thereon, the number of hospital based centers increased at a slow pace with only 
four centers in the U.S. treating with protons by the end of 2006. However, in the last 
decade, proton therapy has seen a tremendous growth in the U.S. and internationally. 
Proton therapy is becoming increasingly available in the U.S. with close to 25 centers 
treating patients (6). Worldwide, there are close to 70 centers that are treating patients 
with protons with another 50-70 facilities in some stage of construction or planning (7). 
While the availability of proton therapy is increasing, so are the clinical trials that 
compare the efficacy of proton therapy with conventional radiation. With increasing 
adoption of proton therapy, the number of patients that are treated with proton therapy 
is increasing rapidly and thereby providing more data for comparison of clinical 
outcomes. The superior dose distributions afforded by proton therapy make it an ideal 
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form of treatment for pediatric patients, re-treatment cases, and complicated targets 
where conventional radiation therapy may not yield optimum plans. 
1.2. Rationale for Proton Therapy 
The main goal of radiation therapy is to deposit the dose in cancer cells while 
minimizing radiation to the normal tissue cells. This is generally achieved by various 
means i.e. (i) using multiple beam angles (ii) selecting the appropriate beam angles to 
minimize, normal tissue exposure, (iii) use of intensity modulation, where beams are 
modulated to conform isodoses to the target volume, and (iv) exploiting the depth dose 
characteristics of the type of radiation. The main advantage of proton therapy over 
conventional electron and photon therapies is the characteristics of its depth dose 
distribution (Figure 1). According to Bethe-Bloch equation (8), the linear stopping power 
of a charged particle traversing in matter is due to collisional and radiative processes 
and is given by: 
…………………….....Eqn. 1 
with the following definitions: v= velocity of the charged particle, ze= charge of the 
charged particle, Z= atomic number of absorber material, N= number density of 
absorber atoms, Me=electron rest mass, e= electron charge, I= average excitation and 
ionization potential, β=v/c, c=velocity of light. At low charged particle energies, β<<1, 
the above equation reduces to:  
……………………………...………...Eqn. 2 
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Figure 2 shows the stopping power of a 200 MeV proton beam in water. It can be 
seen that due to the 1/v2 dependence, the stopping power increases sharply when the 
residual energy of the beam is below 30 MeV. It is this phenomenon that gives rise to 
the Bragg peak (figure 1). This is a major advantage over conventional radiotherapy 
using photons. The photon depth dose, when entering a medium, has an initial build up 
before reaching maximum and then decreases exponentially. Since most tumors 
treated with radiotherapy are located deeper than the depth of maximum dose, this 
effectively means that a photon beam will deposit more dose in the normal tissue 
upstream of the tumor. With proton therapy, one could position the location of Bragg 
Figure 1.  (Left) Comparison of depth dose characteristics between a proton SOBP 
beam and an X-ray beam. The SOBP beam is composed of 12 elemental Bragg 
peaks with variable weights to create a SOBP (Right) Even when AP/PA 
configuration of beams is used; there is advantage of using proton beam due to 
reduced entrance dose and no dose to deep tissue. Figure obtained from 
www.radiotherapie.nl. 
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peak inside the target thereby reducing the dose to the overlying tissue. Another 
advantage of the proton beam is its ability to completely stop in the tissue and thus give 
no dose to any tissue beyond the target. A photon beam, due to its exponential decline, 
will keep on depositing substantial dose to underlying tissue. Even when using an 
AP/PA beam arrangement for photons, there is a substantial reduction in integral dose 
for shallow and deep tissue using the proton therapy (figure 1). 
 
 
 
1.3. Types of proton therapy 
The proton beam generated by the cyclotron is generally a very narrow beam 
and needs to be spread to cover the required field cross-section to be useful clinically. 
There are two commonly used techniques to achieve this: (i) Passive Scattering, and (ii) 
Active Scanning.  
Figure 2. Stopping power of 200 MeV proton beam in water. Plot obtained from 
physics.nist.gov 
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1.3.1. Passive Scattering Systems 
In order for a narrow beam to be useful for clinical treatments, it has to be spread 
in the lateral as well as depth directions. For cyclotrons, the spreading in the depth 
direction is typically accomplished by a range modulator (RM) (9) (figure 3). The RM 
wheel has many tracks and steps of variable thickness corresponding to the range of 
energies desired for clinical use. The incident energy of a proton beam is reduced 
relative to the thickness of the material in the beam path. In order to generate a Spread 
Out Bragg Peak (SOBP) from a pristine peak, the RM wheel can be programmed to 
introduce varying thicknesses of material in the beam path as a function of time. As 
each step is a different thickness, a spectrum of output ranges can be obtained. By 
passing the pristine beam from each step for a set amount of time, the intensity of the 
output peak can be controlled. By adding many modulated peaks of different energy 
and intensity, an SOBP is obtained (figure 3).  
Figure 3. (Left) An example of modulator wheel used by IBA (Louvain La Neuve, 
Belgium) system. Image obtained from Kooy et al (10). (right) Demonstration of how 
elemental Bragg peaks are added to form a spread out Bragg peak (SOBP) beam.  
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The broadening of narrow beam in the lateral direction is performed through a 
dual foil scatter system (11). The first scatterer is a uniform thickness material in the 
beam path that is generally made of high Z material. The output beam profile after the 
first scatterer is approximately a forward peaked Gaussian shape that must be further 
flattened for clinical usability. A second scatterer that has a non-uniform thickness or 
atomic composition is used to produce a flat or nearly flat distribution at the patient 
plane.   
Once a beam is spread laterally and in the depth direction, a rectangular uniform 
dose distribution in a water phantom can be obtained. However, further modifications 
are required to the beam profile to fully exploit the potential of proton therapy. By 
adding beam modifying hardware such as apertures and range compensators (12), a 
flat beam profile can be conformed to patient specific target. An aperture (figure 4) is a 
piece of hardware that shapes the lateral extent of proton beam to the target outline in 
beam’s eye view. Generally, apertures are made up of brass of sufficient thickness to 
completely stop the unwanted protons that are outside the projection of the treatment 
volume. The shape of the aperture is determined during the treatment planning process 
and the design is typically transferred to a CNC machine for milling. Use of apertures 
allows lateral conformality of the proton beam to the target. The conformality on the 
distal side of the target is achieved through the use of a range compensator (figure 4). 
A range compensator is generally made up of acrylic or wax and has spatially varying 
thickness that is dictated by the geometry of the target volume. A range compensator is 
able to account for spatial changes in the patient surface, inhomogeneities, and distal 
tumor shape. Both compensator and aperture are beam specific devices that are 
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custom built for each patient field. The full schematic of passive scattering system is 
shown in figure 5.  
 
Figure 4. Patient specific hardware for passive scattering and uniform scanning: 
aperture (left) and compensator (right).  Apertures are used to conform the isodoses 
laterally to the target volume. Compensators provide conformality of isodoses at the 
distal side of the target. 
 
As seen, a passive scattering system is able to conform isodoses to the desired 
target in both the lateral and distal directions. However, as the modulation of the beam 
is fixed, the beam cannot be conformed to the target in the proximal direction. This can 
be seen in figure 5, where there is increased dose at the proximal side of the target. In 
addition, passive scattering systems require patient specific hardware that leads to 
higher cost and increased lead up times. Furthermore, beam modifiers produce 
additional neutron background that has potential to increase the risk of secondary 
cancers. 
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1.3.2. Active Scanning Systems 
There are currently two main technologies that are used by active scanning 
systems: uniform scanning (US) and pencil beam scanning (PBS). For the US systems 
(figure 6), a constant intensity proton beam is scanned across the field area defined by 
the snout resulting in a flat uniform profile. For the IBA systems, the beam is scanned at 
30Hz in vertical direction and 3Hz in horizontal direction. The advantage of US over 
passive scattering is that protons are able to maintain their energy as they do not have 
to travel through as much scattering material. In addition, there is reduction of 
unwanted scattered radiation due to removal of scatterers. However, the US systems 
still require the use of patient specific apertures and compensators for conforming 
isodoses to the target. The US systems produce a square or a circular uniform field that 
needs to be collimated to the lateral extent of the target. Similarly, the conformality in 
the distal side of the target is achieved by placing a variable thickness compensator. 
Both aperture and compensator are mounted on the snout close to the patient surface 
to reduce geometrical penumbra due to aperture. 
 
Figure 5. Schematic of a Passive Scattering system. Image obtained from 
medicalphysicsweb.com 
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Figure 6. Schematic of a proton pencil beam scanning system. Dose is deposited 
using individual spots that can be conformed to the target volume.  
Figure 5. Schematic of an IBA uniform scanning system. A constant intensity proton 
beam is scanned across the field in both horizontal and vertical direction to produce 
a flat dose profile. By placing an aperture and a compensator at the end of the snout, 
the field can be conformed to a target. 
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A pencil beam scanning system (figure 7) enables dose conformality in the 
proximal, distal and lateral directions without the need for any beam specific hardware. 
The dose is deposited in the form of many narrow individual pencil beams (spots) of 
varying energy and intensity. The lateral position of the spots is controlled by varying 
the current on scanning magnets in the X and Y directions. The longitudinal position of 
the spot (Bragg peak) is controlling by varying the energy of the proton beam. A 3-D 
target is divided into many layers and dose is deposited sequentially from distal to 
proximal layer. Within each layer, dose is deposited by spots, whose location and 
intensity is determined by the planning system. By positioning the spots to the outline of 
the target volume, the dose distribution can be conformed to the target in all directions. 
Pencil beam scanning systems provide numerous advantages over US and PS systems 
such as, (i) no need for field specific hardware, (ii) low neutron background due to fewer 
beam modifiers, (iii) higher effective dose rate as scanning is limited to the extent of the 
target instead of the whole field when compared to uniform scanning. The main 
disadvantage of PBS over US or PS systems is sensitivity to motion in terms of 
interplay effect i.e. relative motion between the delivery of spots and moving target 
region and anatomy. Due to time dependent nature of PBS delivery, there is a 
possibility of a target moving out of the position within the delivery of layer. Mitigation 
strategies for the interplay effect have been developed such as repainting of layers or 
repainting of the entire treatment volume (13). 
Another difference between passive scattering, uniform scanning and pencil 
beam system is from the treatment planning point of view. Both US and PS treatment 
planning is performed using forward planning methods. The target and OAR doses are 
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manipulated by iteratively varying one of the many treatment parameters such as 
range, modulation, aperture opening, and compensator thickness. In PBS, treatment 
planning is performed using inverse optimization similar to intensity modulated radiation 
therapy (IMRT). The treatment planner will provide the planning system with a set of 
instructions in the form of target and OAR dose-volume objectives and constraints, and 
the planning system will come out with a solution that best matches the specified 
criteria. For PBS plans, users are able to specify energy layer spacing and spot spacing 
for each beam before dose optimization. 
1.4. Proton Interactions in Matter 
Protons interact with matter in mainly three types of interactions, (i) coulomb 
interactions with orbital electrons, (ii) coulomb interactions with the nucleus, and (iii) 
nuclear interactions.  
Due to the proton’s large mass relative to the electron, most of them will travel in 
a straight line when they are in the vicinity of an orbital electron (figure 8a). In contrast, 
the columbic interaction with nucleus often results in deflection of proton from its 
straight line trajectory. In the entrance region, most of the proton interactions are 
coulombic and cause excitation or ionization of the orbital electrons. Since the mass of 
an electron is ~2000 times smaller than a proton, there is negligible deflection of a 
proton during this interaction. Although inelastic interactions occur in this region, the 
amount of energy transfer for each interaction is small and causes very slight deflection 
of the proton from its original path. As the proton traverses through the media, it keeps 
on losing small increments of energy to orbital electrons. The secondary electrons 
produced in the process have low energies and deposit most of their energy locally. As 
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Figure 7.  Proton interactions in matter. (a) Coulombic interaction of proton with an 
orbital electron causing ionization of the atom. (b)  Coulombic interaction of proton 
with nucleus causing deflection of proton from its straight line trajectory. (c) Example 
of a nuclear interaction where proton collides with the nucleus and produces a recoil 
nucleus, gamma ray, a neutron, and a proton. Figure obtained from Newhauser et el 
(14).  
the velocity of the original proton gradually decreases, it spends more and more time in 
the vicinity of the orbital electron thus gradually increasing the amount of energy 
transfer. The rate of energy loss i.e. linear stopping power formalism provided by Bethe 
and Bloch (equation 1) shows that energy loss is directly proportional to: (i) inverse 
square of proton’s incident velocity, and (ii) density of electrons in the absorber 
material. Both of these dependencies have clinical significance for a proton beam 
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traversing through an absorber material. It is the inverse square dependence on the 
proton’s velocity that gives rise to distinctive high dose peak area in the depth dose 
known as the “Bragg peak “. The dose in the Bragg peak is mainly due to low energy 
protons spending more time in the vicinity of orbital electrons and transferring maximum 
energy to them, which is deposited locally thus creating a sharp Bragg peak. The range 
of a proton beam inside a medium is dictated by the initial proton beam energy and the 
electron density of the absorber medium. Since the physical density of a material is 
closely related to electron density for human tissues, the range of protons in a material 
is mainly a function of density of the material. Clinically, this means that proton energy 
required to treat a tumor depends on the physical depth of the tumor as well as the 
density of the overlying tissue.  
In terms of coulombic interactions with the atomic nucleus (figure 8b), the proton 
gets deflected from its straight line path due to the large mass of the nucleus. Although 
large deflections of the primary proton can occur, most of deflections are small. 
However, the cumulative impact of many such small events can lead to an increase in 
angular spread of the proton beam as its travels through an absorber medium. This 
gradual increase in angular distribution is called multiple coulomb scattering. Due to 
multiple coulomb scattering (MCS), the trajectory of a particle traversing a medium has 
multiple short straight line paths. A given proton will undergo a random number of 
interactions and will lose varying amounts of energy during each interaction. These 
statistical fluctuations in energy loss and number of interactions for each proton lead to 
a spread of proton energies at any particular depth. This phenomena is called range 
straggling and has an impact of increasing the width of Bragg peak. In addition, the 
14 
 
 
 
incident proton beam is not completely mono-energetic but also has an inherent energy 
spread that also contributes to widening of the Bragg peak. The most accepted theory 
to explain the characteristics of MCS as a function of particle type, energy and absorber 
material was given by Moliere (15). The angular distribution of protons that undergo 
MCS is approximately Gaussian. Moliere theory provides a formalism to calculate the 
width of the Gaussian distribution from the incident proton energy and target thickness. 
In terms of clinical significance, MCS determines the sharpness of the lateral 
penumbra. As the mass of the proton is relatively light compared to a nucleus, the 
amount of nuclear coulombic deflections from a straight line path is greater than for 
electron interactions thus increasing the lateral penumbra. In contrast, for particles like 
carbon, the deflection angle is smaller thus resulting in overall sharper lateral 
penumbra. Clinically, sharper penumbra is an advantage to reduce the normal tissue 
dose. 
A very small fraction of incident protons will undergo direct head-on collision with 
the nucleus of an atom as shown in figure 8c. There are three types of nuclear 
interactions, (i) elastic, (ii) inelastic, and (iii) non-elastic. With elastic interactions, the 
kinetic energy of the incident proton is conserved and the proton scatters off the target 
nucleus. MCS, single or plural scattering are examples of elastic nuclear interactions. 
With non-elastic interactions, the kinetic energy is not conserved and secondary 
particles are generated that carry energy away from the interaction site. An incident 
proton bombards the target nucleus to cause break-up or elevation to an excited state. 
Inelastic interactions are a special case of non-elastic as part of the incident proton 
energy is used for excitation of the nucleus but the final nucleus is same as bombarded 
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nucleus. Generally, nuclear interactions are mostly referred to non-elastic interactions in 
literature. For non-elastic interactions, part of the incident proton energy is used to 
overcome the binding energy of the nucleus. The types of secondary particles that are 
possible are protons, neutrons, gammas and heavy nuclear fragments. There are two 
types of secondary particles that may be formed: short range charged particles and 
long range neutral particles. The secondary particles such as neutrons and gammas 
have relatively high range and thus end up depositing dose away from the local site. On 
the other hand, short range secondary particles such as alphas, protons and nuclear 
fragments will deposit most of their energy locally. The probability of a proton 
undergoing nuclear interaction increases with energy and is shown in figure 9 (16). 
 
Figure 8. Nonelastic interaction probability as a function of proton range in water. 
Figure obtained from Gottschalk (16).  
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Figure 9. Depth dose for a 160 MeV proton beam with (solid line) and without (dashed 
line) nuclear interactions. The solid curve is an actual Bragg peak. The dashed line is 
simulated using MC with nuclear reactions switched off. Figure obtained from Berger et 
al (17). 
In terms of clinical significance, nuclear interactions result in reduction of primary 
proton fluence thus changing the shape of Bragg peak (figure 10). The mean fluence 
reduction as given by Bortfeld (18) is 1.2% g-1 cm2. The long range particles such as 
gammas and neutrons will remove dose from the Bragg peak and add dose to the 
surroundings. The short range particles have greater angular spread and carry lower 
energies that are deposited locally but result in a low dose region around the primary 
proton dose. This low dose region is referred to as nuclear halo in the literature (19, 
20). It is critical to account for the nuclear halo in commissioning of proton spot 
scanning as excluding it could result in dose differences of up to 15% (19). Generally, 
the measurements of nuclear halo are difficult due to its low intensity and corrections 
are performed based on Monte-Carlo simulations. 
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1.5. Dose Calculation Algorithms 
The following section is based on work by Clasie et al (21), Schaffner et al (22), 
Sokup et al (23), Newhauser et al (14) and Hong et al (24)  
The currently available treatment planning systems for proton spot scanning can 
be divided into two classes, analytical and Monte-Carlo (MC) algorithms. Pencil beam 
algorithms are analytical in nature as the output dose distribution is the same for the 
same set of input parameters. On the other hand, MC dose calculation algorithms use 
random sampling of interaction cross-sections to simulate individual particles 
trajectories. The statistical nature of MC dose scoring can result in variation of output 
dose distribution based on the number of particle histories in the simulations. However, 
the statistical uncertainty decreases as the number of histories is increased. 
1.5.1. Pencil Beam algorithms for Proton Spot Scanning 
In the pencil beam analytical (PBA) algorithms, a wide proton beam is divided 
into many narrow mini-beams for dose calculation. In fact, these mini-beams are 
generally referred to as pencil beams with corresponding dose calculation algorithms 
called pencil beam algorithms. The PBA algorithms model the patient as a set of 
laterally infinite homogenous slabs whereas material encountered by the central axis of 
pencil beam is considered to be the material composition of the slab along the depth. 
This approach leads to PBA algorithms being insensitive to lateral inhomogeneities. 
The general formalism for calculating dose to water is the convolution of proton fluence 
ø with an elemental pencil beam dose distribution called dose kernel, k. k represents 
dose deposited in water by an infinitesimally narrow proton pencil beam. For a subset of 
pencil beams, the dose deposited at a point is given by: 
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……..Eqn. 3 
The convolution is replaced by a summation in the above equation to calculate 
dose on a discrete grid.  The above formalism uses wer as water equivalent range at 
the central axis of the beam to account for inhomogeneities. The dose kernel, k, is 
terms of dose deposited at position (x,y,z) by a pencil beam along the z-axis and 
positioned at (x0, y0) is given by: 
…..Eqn. 4 
ID= integral dose obtained from depth-dose look up table 
wer= water equivalent range along the central axis of the beam. 
σx,  σy are standard deviation of spot intensity (spot sigmas) in x and y respectively 
Np+ is the number of protons in the beam spot. 
The integral depth dose (IDs) is obtained either by measurement or through MC 
simulations. The measurements are performed by using a wide area detector such as a 
Bragg peak (BP) chamber in a water tank. The beam is composed of a single spot that 
is incident at the central axis of the BP chamber. Such measurements are inherently 
difficult and time consuming due to need of high resolution in depth direction so as to 
capture the true shape of the Bragg peak. The alignment of the BP chamber is also 
critical to obtain correct ratio of Bragg peak to entrance region dose. For this reason, 
the measurements are sometimes fit to MC simulated IDs to obtain the energy spread 
for each available energy. Most of the dose kernels have some form of Gaussian 
function in the x and y directions to account for transport for proton spots through a 
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media. The Gaussian approximation is able to account for beam divergence and 
multiple coulomb scattering. However, there is a low dose envelope due to nuclear 
interactions called “nuclear halo” centered on a Gaussian profile. The corrections for 
nuclear halo are sometimes applied by adding a second Gaussian profile with a larger 
sigma or by modeling spots using non-Gaussian functions. 
1.5.2. Monte Carlo (MC) Algorithms for Proton Spot Scanning   
Dose calculation using MC algorithms generally starts at the exit plane of the 
nozzle where protons are tracked in the ensuing air gap, beam modifiers and lastly 
patient. The beam information at the nozzle exit is stored in a file, called “phase space”, 
which has information about the particle type, energy distribution, lateral profile, and 
divergence. For each beam energy, the phase space data can be generated from 
measurements or MC simulations of the nozzle and upstream components of the beam 
line. The same phase space data can be used for all patients as there is no change in 
the beam components on the source side of the beam. The MC simulation starts by 
randomly picking particles from the phase space distribution and transporting them 
through beam modifying devices, air gaps, and finally inside the patient. An individual 
particle will undergo physical interactions based on the interaction cross-sections in the 
medium of absorption. The interaction models for electromagnetic and nuclear 
interactions are based on theoretical models, parameterization, or experimental data. 
Energy transfer occurs when primary particles excite or dislodge orbital electrons or 
undergo nuclear interactions to produce neutrons, deuterons, tritons, alphas, electrons, 
and secondary protons. These secondary particles are tracked individually until they 
their energy falls below a certain threshold when all the energy is assumed to be 
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deposited locally.  A very large number of particle histories have to be run, tracked, and 
doses scored to achieve required statistical uncertainty in the dose distribution.  
MC methods are generally considered the gold standard for dose calculation due 
to their high accuracy. However, most MC methods are too slow for routine dose 
calculations. The statistical uncertainty for dose in a voxel using MC algorithm is 
inversely proportional to the square root of the number of particles simulated. 
Therefore, to improve the statistical uncertainty by a factor of two, one has to simulate 
four times as many particles. Most of the MC dose calculations for treatment plans have 
been performed using one of the research based codes. The clinical use of MC for 
dose calculation had been very limited due to the lack of commercial offering by any 
vendors until recently. With the advancement in computing resources, it should now be 
possible to routinely calculate doses using MC methods fast and efficiently. In fact, two 
vendors (RaySearch Inc., Garden City, NY, and Varian Medical Systems, Palo Alto, CA) 
have recently offered commercial MC dose calculation algorithms for proton spot 
scanning. With increasing sophistication of computers, it is likely that MC methods will 
overtake analytical methods for dose calculation in the very near future. 
1.6. Project Overview 
Proton therapy is becoming a mainstream cancer treatment option. With the 
advancement of proton therapy, newer and more accurate dose calculation engines are 
being released in the market. However unlike photons, there is a great dearth of 
commissioning and validation information for proton treatment planning systems (TPS). 
Unlike photons, there are no AAPM task group reports that can serve as a guidance 
document.  This dissertation provides validation of two commercially available dose 
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calculation engines, i.e. Analytical and Monte Carlo distributed by RaySearch America. 
In chapter 2, we provide results of the commissioning and validation of RayStation’s 
analytical algorithm for proton spot scanning. The beam data measurements were 
performed in the fixed gantry room of the Seattle Cancer Care Alliance Proton Therapy 
Center (SCCA-PT). A journal article summarizing the findings of chapter 2 was 
successfully published in International Journal of Proton Therapy in March 2016. In 
chapter 3, the dosimetric validation of RayStation’s Monte Carlo (RS-MC) algorithm will 
be described including a discussion of simulation and measurement techniques. A 
beam model (G-MC) for the gantry room of the SCCA-PT center was created in the 
GATE code. The benchmarking between G-MC and RS-MC was performed for a 
variety of simulations in virtual homogenous and heterogeneous phantoms. In addition, 
validation of RS-MC was also performed against measurements in similar geometries to 
the simulations. The results of the validation were summarized in a manuscript that is 
published in the journal Physics in Medicine and Biology. In chapter 4, the G-MC model 
was used to evaluate a newly available ceramic fiducial marker for ocular melanoma. 
Fiducial markers are commonly used in radiation therapy for image guidance thus 
reducing the treatment margins. Most fiducial markers are however made up of high 
atomic number material that causes dose shadows in the underlying tissue. Ceramic 
markers have the promise to reduce the dose shadow while still maintaining the visibility 
on x-rays. We used our G-MC beam model to study the dose shadows caused by the 
marker and validated the results with measurements. The results of the evaluation were 
published in a technical note in Biomedical Physics and Engineering Express in Feb 
2017.  
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CHAPTER 2 CLINICAL COMMISSIONING AND COMPREHENSIVE 
EVALUATION OF A COMMERCIALLY AVAILABLE PENCIL BEAM 
SCANNING TREATMENT PLANNING SYSTEM FOR PROTON 
THERAPY 
 
2.1. Introduction  
The physical advantages offered by protons due to their finite range and nature 
of their depth dose is leading to a surge in the number of new centers opening in the 
world and heavily in the United States (25). The current technologies used to deliver 
proton therapy are passive-scattering (PS), uniform scanning (US), and pencil beam 
scanning (PBS) (26-30). With PS, the lateral enlargement of the proton beam is done 
by placing either single or dual scatterers in the beam path. A range modulator wheel 
that is placed in the beam path before the scatterers rotates rapidly to generate a 
sequence of Bragg peaks with different ranges and weights. All these peaks are added 
together to produce a spread out Bragg peak (SOBP). A number of range modulator 
wheels are generally required to cover the clinically required combination of SOBPs. 
Another method of laterally spreading beam is through the use of uniform scanning, in 
which a proton beam is continuously scanned laterally using magnets. The proton beam 
scans a fixed pattern in the field for each layer. The relative weights of layers are 
chosen to produce a flat dose in SOBP. A range modulator wheel present in the beam 
path indexes to a particular track for the complete delivery of the layer. Once a layer 
has been delivered, the wheel rotates to next track with a different thickness. Both the 
passive scattering and US methods require field specific hardware such as 
compensators and apertures for target dose conformity.  
23 
 
 
 
PBS scanning is a relatively newer technology that can reduce the need for field-
specific hardware (e.g. apertures and compensators) and offers better dose 
conformation to the target (31). In PBS beam delivery, a three dimensional target is 
divided into many slices. The dose is deposited from the most distal slice to the most 
proximal slice sequentially. Within each slice, the dose is deposited through individual 
spots that can have unique intensity and position. A major difference between PBS and 
US/PS comes due to the planning techniques used; PBS utilizes inverse planning 
techniques while US/PS treatment planning is done through forward planning methods. 
This is a big advantage for PBS as inverse planning provides the ability to have multiple 
dose levels in a target within a single field, also called dose painting. In addition, a PBS 
beam can be optimized to have both distal and proximal conformity of dose around the 
target. 
Proton therapy has been clinically used since 1954 but there is still very limited 
data available that could be used as a resource for commissioning and verification of 
treatment planning beam models. In the US there are multiple commercial systems that 
offer the capabilities of planning with PBS, i.e. CMS XiO (Elekta CMS Software, St. 
Louis, Missouri), Varian Eclipse (Varian Medical Systems, Inc., Palo Alto, CA), and 
RayStation (RaySearch Americas, Inc., Garden City, NY). Gillin et al. (32) have 
provided their experiences of commissioning Varian Eclipse planning system on a 
Hitachi ProBeat delivery system at University of Texas M.D. Anderson Cancer Proton 
Therapy Center, Houston (PTC-H). The PTC-H system utilizes a synchrotron with the 
capability of delivering 94 discrete energies. Another study done at PTC-H by Zhu et al. 
(33) compared the beam models based on single and double Gaussian approximations 
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of the in-air spot profiles. Both of these studies were done for the Varian Eclipse 
planning system and Hitachi ProBeat delivery system. Thus far, there are no published 
reports about the commissioning methodology for RayStation TPS for proton PBS 
system of IBA’s universal nozzle. Accordingly, this report presents details of the 
commissioning and verification process of RayStation PBS at our center. It is not 
intended that this should be a guideline or recommendation for the use of RayStation 
PBS planning, but other potential users may benefit from the approaches taken for the 
commissioning process.  
The Seattle Proton Therapy Center (SPTC) is the first proton therapy center in 
the Pacific Northwest Region. The center has four treatment rooms that comprise a full 
360 degree capable gantry room, two inclined beam rooms, and one fixed horizontal 
beam room (34). The gantry and fixed beam rooms have the capability to deliver the 
treatments using the PBS technology. Initially, the fixed beam room was commissioned 
in CMS XiO treatment planning system to plan with the PBS methods. After the 
RayStation (RS) planning system received FDA approval, the fixed beam room was re-
commissioned in RS. The commissioning was completed in July 2014 and the system 
was released for clinical use.  
2.2. Materials and Methods 
2.2.1. The Fixed Beam Pencil Beam Delivery System 
The SPTC fixed pencil beam delivery system is an IBA universal nozzle (Figure 
11) that provides the proton beam at a single horizontal gantry angle. The protons are 
accelerated to 230 MeV in an IBA cyclotron before being extracted and transported to 
the beam line. The proton beam line consists of a degrader, energy selection system, 
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dipoles, quadrupoles and steering magnets. The proton beam spot is magnetically 
scanned through each layer of the target volume. Each spot within a layer can have 
unique MU ranging from minimum of 0.02 to maximum of 11. A three-dimensional 
target is divided into many slices and proton beams sequentially paint the dose from 
deepest slice to the most superficial slice. The system provides the clinically usable 
ranges as measured in water from 7.5 to 32.6 cm that correspond to proton energies 
98.5 to 228.5 MeV respectively. The maximum field size available is 40 cm x 30 cm with 
spot sigma in air that varies from 3.5 mm for highest energy to 7.5 mm for lowest 
energy at the isocenter plane.  
Figure 110: Schematic of the pencil beam delivery system at Seattle Proton Therapy 
Center 
2.2.2. The RayStation treatment planning system 
The RayStation (RS) treatment planning system distributed by RaySearch 
America was commissioned for delivery of PBS treatments. The beam data 
requirements for the commissioning were obtained from the vendor. The initial version 
(4.51) of RayStation models proton fluence through the air before hitting the patient or 
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phantom medium using a single Gaussian approximation. Correspondingly, the 
transport in the medium is performed using two Gaussian approximations. The first 
Gaussian accounts for the small angle multiple coulombs scattering (MCS) while the 
second Gaussian accounts for the nuclear interactions and larger angle MCS also 
called “nuclear halo”. In order to accurately account for the lateral inhomogeneities 
within the medium, each spot is split into 19 sub-spots for dose calculations. An 
example of measured vs the calculated spot profiles in air is shown in Figure 12. 
 
Figure 111: Example of spot profile measured and calculated in TPS. The RayStation 
TPS uses sub-spot resolution of 19. 
 
2.2.3. Measurement of Beam Commissioning Data 
The beam data measurements were done at 18 energies that were selected 
from the available energies of 98.5 to 228.5 MeV. These 18 energies were sampled at 
the regular interval of 7.5 MeV in accordance with TPS vendor‘s recommendation. In 
our clinic, the range of the beam is defined at the distal 90% of the Bragg peak (or 
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spread out Bragg peak). Table 1 lists the energies along with their corresponding 
ranges that were used for beam data measurements.   
Table 1: 18 energies were selected from the available pool for beam data 
measurements. The spots for each beam were placed in a 25 mm rectilinear grid 
pattern for a total scanning area of 10.5 X 10.5 cm2. Each spot was assigned MU value 
of 1 thus resulting in total MU of 1849 for the beam. 
 
2.2.3.1. Integrated Depth Dose Measurements 
The integrated depth dose curves (IDDC) were obtained for each of the 18 
proton energies by scanning a large area detector in a proton beam with a continuous 
mono energetic single spot beam incident on the central axis. As the only available 
beam direction is horizontal, the presence of phantom wall in the beam direction 
requires the careful determination of water equivalent thickness (WET) of the wall. A 
custom phantom with 1D scanning abilities was manufactured in house. The phantom 
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has dimensions of 25 x 25 cm2 in plane normal to the beam direction, with scanning 
ability of up to 36 cm in beam direction. This phantom has a front entrance window 
made up of acrylic with 1.45 mm thickness. By using a tank with such a thin window, 
any uncertainties in the determination of wall WET are minimized.  
The IDDCs were measured using an 8 cm diameter integrating PTW Bragg Peak 
ionization chamber (PTW, Germany) and Sun Nuclear PC Electrometer (Sun Nuclear 
Corp., FL, USA). A large area detector such as the 8 cm Bragg peak chamber helps 
ensure that spots are adequately captured in the lateral direction. Integrated charge 
measurements at the interval of 1 mm were acquired for the entire length of the Bragg 
peak. The phantom was set up with the front face positioned at the isocenter. At each 
interval, at least 10 measurements were acquired to minimize the impact of any noise in 
the resulting data. The measured depth dose curves were shifted to account for the 
WET of the tank wall and effective point of measurement of Bragg peak chamber (4.2 
mm). Generally these measurements are the most time consuming and therefore great 
consideration should be given to the methodology employed. The IDDC’s were 
normalized to the same nominal value of 100 for all 18 beams and are shown in Figure 
13. 
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Figure 112: Integrated depth doses acquired using 8 cm Bragg Peak Chamber in a 
field with a single spot positioned on the central axis of the beam. The curves are 
normalized to common value of 100. 
 
2.2.3.2. Spot Sigma Size and Virtual Source Position: 
The spot profile characteristics are an essential part of the commissioning 
measurements. These measurements are performed in air using a high resolution 2D 
scintillation detector. The recommendation of the TPS vendor is to perform these 
measurements in at least five planes that cover the distances suitable for clinical use.  
We used the Lynx 2D scintillation imager (IBA Dosimetry, Germany) for the 
measurements of spot profiles at five different planes; isocenter plane, 10 cm 
upstream, 10 cm downstream, 20 cm upstream, and 20 cm downstream. The spot 
profiles were measured in air (no build up) for the selected 18 energies. The planning 
system assumes that spot shapes are invariant with respect to lateral displacement in 
the scanned field. Figure 14 shows an example of a field that was created to measure 
spot sigmas. Sigmas for all 5 spots in a field were measured in both X and Y direction, 
with average values used in the planning system. A 2D elliptical Gaussian fitting was 
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used for the spot profile to determine the sigmas. Figure 15 shows the spot profiles for 
three given energies at isocenter plane. 
The spot patterns obtained at different planes were used to calculate the 
divergence and subsequently virtual source-to-axis distance (SAD). The centroid of the 
spot can be plotted as a function of distance to obtain the SAD. As the scanning 
magnets in X direction are upstream of Y direction, the virtual SAD should be higher for 
X axis. The SAD values used in the TPS were averaged over all 18 energies. 
 
Figure 113: (a) Field with 5 spots was created to measure spot sigmas. The sigmas 
values were averaged for these 5 spots, (b) Variation of X and Y sigmas with energy at 
the isocenter plane. 
 
2.2.3.3. Absolute Beam Calibration 
The absolute beam calibration is based on measurements made in uniform 
unmodified single layer fields. Square 10 x 10 cm2 fields were created with spots 
arranged in a uniform grid pattern with center-to-center spot of 2.5 mm. Each spot was 
assigned a value of 1 MU to create a laterally uniform profile (Figure 16). The RS TPS 
requires the measurements to be made approximately midway between 1 cm depth and 
the position corresponding to one half of the Bragg peak maximum. A water tank was 
set up with an ADCL calibrated PPC05 parallel plate ion chamber and electrometer for 
these measurements. The measurement parameters such as air gap, source to 
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phantom distance, detector depth, field size, and field specifications were clearly 
documented as these are needed for the beam modelling. The physical doses 
measured were scaled up by a factor of 1.1 so as to account for proton RBE. The 
results of the measurements are given in Table 1. 
 
 
Figure 114: Spot profiles for three energies at isocenter plane in air. 
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Figure 115: Single layer 10x10 cm fields used for absolute calibration of the beam.  
 
The absolute relationship between dose-MU was performed in two steps. First, a 
relative model was obtained from RayStation based on the normalized IDDCs and dose 
measurements in single layer fields. This relative beam model was necessary to 
determine relative spot weights needed to create a uniform SOBP. It was then used to 
optimize a square field of 10 x 10 cm2, Range = 20 cm, SOBP Width =10 cm to deliver 
100 cGy (RBE) in the center of the SOBP. This beam is used for absolute calibration of 
the machine utilizing the IAEA TRS-398 protocol. The relation between dose and MU is 
arbitrary and completely dependent on user’s clinical preferences. At our center, a 
value of 1000 MUs was chosen to deliver 1 Gy (RBE) in the center of SOBP for the 
above defined field. Therefore, the second step of establishing dose-MU relationship 
involved scaling the whole beam model so that 1000 MUs are required to deliver 1 cGy 
(RBE) in the center of SOBP for the calibration beam.  
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2.2.3.4. Beam Modelling Process 
Currently, the beam modelling for pencil beam scanning is done directly by the 
vendor. All the beam data as well as non dosimetric data was sent to RaySearch. The 
name and ID of the machine, snouts, and range shifters were made to match the 
machine parameters defined in the Mosaiq (Elekta Medical Systems, Sunnyvale, CA)) 
Oncology Information System.  The coordinate system for couch motion, gantry angles, 
and field scanning area should also be clearly defined. 
2.2.4. Verification of Beam Model 
The verification of the beam model consisted of evaluation of many different 
aspects; (i) spot profile, (ii) depth doses for single layer plans, (iii) absolute dose vs field 
size for single layers, (iv) depth doses of optimized SOBP plans, (v) absolute doses for 
SOBP plans, (vi) lateral dose profiles, and (vii) patient specific QA of mock phantom 
plans. 
Table 2: Single layer plans corresponding to the given energies were created for field 
sizes 5x5 to 29x29 cm2. Point dose measurements were made at above given depths, 
in entrance region and near Bragg peak. 
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To verify the modelled spot sizes, various phantom plans with a single spot 
located on the central axis were generated. The spot profile characteristics at the 
surface of the phantom were compared to measurement data obtained through Lynx 
2D scintillator imager in the same set up. A maximum discrepancy of 1 mm was allowed 
between measured and calculated spot sigmas. In order to evaluate the change in dose 
at the central axis with field size, single layer (mono-energetic) beams were generated 
for square fields with sizes of 5 x 5, 10 x 10, 15 x 15, 20 x 20, 25 x 25, and 29 x 29 cm2. 
These single layer beams have spots arranged in a uniform grid fashion with each spot 
assigned the same MU value. Eight different energies (Table 2) were sampled from the 
entire available range for the purpose of this evaluation. The combination of six field 
sizes and eight different energies resulted in total of 48 unique beams. Point dose 
measurements were made at two different locations along the Bragg peak, i.e. in the 
flat plateau region and another point near the Bragg peak. Furthermore, depth doses 
for 10 x10 cm field were also measured through Multi-layer Ionization Chamber (MLIC, 
IBA Dosimetry, Germany) and compared to the depth doses calculated in a virtual 
phantom. The point dose measurements were considered to be acceptable if 
measurements were within +/-3% of the calculated. The pass criteria for the depth 
doses were to have accuracy of the distal edge within 1 mm and local point-to-point 
dose difference to be <3%.  
To validate point doses, depth dose curves, and lateral profiles phantom plans 
were created to deliver uniform dose to box targets. 3-dimensional targets 
corresponding to field sizes of 5x5 to 25x25 cm2, ranges 7.5 to 32.5 cm, and widths 0.5 
to 22 cm were created in a phantom. Each target was inversely planned to deliver a 
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uniform dose within the SOBP region using a single beam. Figure 17 shows an 
example plan corresponding to range of 22 cm, SOBP width 10 cm, and field size of 10 
x10 cm. A total of 28 plans were made as shown in Table 3. These plans were 
delivered and measurements for point doses, PDDs, and lateral profiles were made. 
Based on the initial verification measurements, additional plans were generated to 
investigate any areas of disagreement in the beam model. The point dose 
measurements were performed using the calibrated PPC05 parallel plate chamber at 
multiple locations in the SOBP region as well in the entrance region. Additionally, for 
plans with field sizes smaller than 10x10 cm2, percent depth doses were obtained using 
the MLIC. Because of the internal electronics, the MLIC cannot be used for any field 
sizes with a side greater than 10 cm.  A depth dose measured through the MLIC 
represents the average charge collected in the central 2.5 cm diameter disc 
corresponding to the size of the ion chamber. Therefore, it is imperative that the uniform 
dose plans have flat profiles in the lateral direction to have a fair comparison with the 
MLIC measurements. The profile measurements were performed using either 
radiographic film or MatrixxPT (IBA Dosimetry) at one to four depths in the SOBP 
region. The following tolerances were employed for analysis:  point dose accuracy +/- 
3% of the calculated; SOBP depth doses +/- 3% at any point along the curve; and 
range accuracy +/- 1 mm. For profiles, a tolerance of 1 mm was allowed for comparison 
of full width half maximum (FWHM) determined by TPS vs measurement. 
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Figure 17: Single beam uniform dose phantom plans for TPS validation were created. 
The beam is inversely optimized to give flat dose profile within the SOBP region. 
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Table 3:  List of uniform dose plans corresponding to given range, SOBP width, and 
field size that were created as part of treatment planning system verification. 
 
The final component of the verification process involved the evaluation of overall 
accuracy for treatment planning and the delivery of realistic clinical plans.  AAPM report 
TG-119 pertaining to IMRT commissioning has provided several planning exercises for 
institutions commissioning their IMRT systems (35-36). In the absence of any such 
standard guidelines for proton spot scanning systems, we adopted some aspects of 
TG-119’s planning and delivery exercise for testing of our system. The CT dataset 
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along with relevant structure as provided by TG-119 were imported into a mock patient 
in the planning system. The report and the associated documentation comes with the 
standard test cases and the planning goals, further details of which can be found on the 
AAPM website. The following beam arrangements were used for developing these 
plans; (i) a three field multi-target, (ii) a two field prostate, (iii) a two field head and neck, 
(iv) a three field C-shape target with easy constraints, and (v) a three field C-shape 
target with difficult constraints. The plans were optimized using the multi field 
optimization (MFO) methods i.e. all beams optimized simultaneously to achieve the 
desired goals. The planner was given the flexibility to achieve the given dose-volume 
goals by creating appropriate objectives and constraints in the prescription. The final 
plans were mapped to a solid water phantom and doses recalculated. Each beam was 
delivered and measurements performed at multiple depths using the MatrixxPT 
detector. The analyses were performed on a beam-by-beam basis and quantified using 
the gamma index. A tolerance of 3% /3 mm was used with a minimum pass rate of 90% 
for gamma index analysis along with a dose threshold of 10%.   
2.3. Results 
2.3.1. Spot Profile Analysis 
The results of the spot analysis are shown in Table 4. The maximum deviation of 
the sigma was noted for lowest energy to be 0.6 mm. The deviation between the 
measured and calculated sigma values in air was found to be within tolerance. The 
observed deviation of spot sigma in Y axis was worse than the X axis. The TPS 
systematically underestimated the Y axis sigmas values by 0.3 to 0.6 mm.  This may be 
attributed to the fact that each spot is composed of 19 sub-spots (Figure 12) to 
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accurately account for lateral inhomogeneities. By representing each spot with 19 sub-
spots, there is a difference in X and Y axis spot projections that could result in modeled 
sigma slightly larger in Y axis. 
Table 4: Results of the spot profile analysis between measured and TPS calculated 
spot sigma values at Isocenter plane in air. The measurements were performed with an 
IBA Lynx. 
 
2.3.2. Depth Doses for 10x10 cm Single Layers 
This is a relative comparison of depth doses measured through the MLIC and 
calculations done in the TPS. The normalization depth was selected to be the same as 
what was initially chosen for absolute calibration (Column 3, Table 1). Figure 18 shows 
the measured and calculated curves for three energies; 98.5, 158.5, and 226 MeV. All 
of the measurements passed the +/-3% criteria between the measured and calculated 
40 
 
 
 
values. The maximum deviation between the measured and calculated range was 
found to be 0.3 mm.  
2.3.3. Point Doses for Single Layers of Different Field Sizes 
The difference between calculated and measured doses for single layer plans 
(Table 2) at two different depths, (i) near Bragg peak and, (ii) in flat entrance region, are 
shown for field sizes 10x10 and 29x29 cm2 in Figure 19a and 19b respectively. A 
positive difference of the plots represent that the measured dose is higher than what is 
calculated by the TPS. The maximum difference for measurements near Bragg peak 
was found to be for largest field size 29 x 29 cm2 at highest energy of 226 MeV to be 
3.4%. A trend can be seen from the graph whereas the discrepancy between measured 
and calculated doses increases with the field size. A similar trend was also observed for 
other field sizes (i.e. 25x25 cm2, 20x20 cm2, and 15x15 cm2). The higher differences for 
larger fields may be attributed to couple of reasons, (i) the use of an 8 cm Bragg peak 
chamber for pristine peak measurements will not collect any charge outside the active 
area, and (ii) the inability of the pencil beam algorithm to accurately account for the low 
dose region produced around the central spot which is called the “nuclear halo.”  . 
 
 
 
 
 
 
Figure 18: Evaluation of single layer depth doses for three different energies. 
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2.3.4. Depth Doses  for SOBP Fields 
For the 18 beams with field sizes smaller than 10x10 cm2 (Table 3), central axis 
depth dose measurements were made using the MLIC detector. The maximum range 
error was seen for plans utilizing the highest energy and found to be less than 1 mm. All 
the points in measured depth doses were within 3% of the calculated values. Four 
cases of the depth dose comparison are shown in the Figure 20 along with the range, 
SOBP width, and field size of the plans. As can be seen, there is excellent agreement 
between measured and calculated depth doses. 
 
Figure 19: The percentage difference between calculated and measured point doses 
for field sizes 10x10  and 29x29 cm2 at depths, (a) in entrance region; and (b) near 
Bragg peak. A positive difference on plot implies that measured dose is higher than 
calculated by TPS. 
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Figure 20: Central axis depth dose comparison for four cases; (a) Range =16 cm, 
SOBP Width = 7 cm, Field Size = 8 x 8 cm2, (b) Range =29 cm, SOBP Width = 10 cm, 
Field Size = 5 x 5 cm2, (c) Range =8.5 cm, SOBP Width = 1 cm, Field Size = 10 x 10 
cm2, and (d) Range =20 cm, SOBP Width = 10 cm, Field Size = 10 x 10 cm2. 
 
2.3.5. Absolute Point Doses for SOBP Fields 
Figures 21 (a-c) summarize the percentage differences between the dose 
calculated by the TPS and measurements made on central axis in the middle of the 
SOBP as a function of range, field size and measurement depth for plans given in 
Table 3.  As can be seen from these results, there are some point dose values outside 
the tolerance of +/-3%. Specifically, the percentage difference is larger than 3% for 
beams with ranges >30 cm, field sizes > 15x15 cm2, and depths>25 cm. This may be 
related to the higher dose differences of up to 3.4% observed for point dose 
verifications in single layer plans. Since the SOBP plans are basically composed of 
many single layers with different weights, the dose differences from unmodified single 
layers are propagated to the complex inversely modulated SOBP plans.  Both the 
impact of not measuring complete charge using the 8 cm bragg peak chamber for 
pristine peak measurements and the inadequacy of the dose algorithm to model low 
dose tails progressively gets worse with the increasing field size and the depth.  The 
43 
 
 
 
maximum difference of 4.5% correlates to beam with range =32cm, SOBP width =5cm, 
field size =25 cm x 10 cm, and depth =31 cm.  
2.3.6. Lateral Dose Profiles 
Using the plans given in Table 2, the profile measurements were made at one to 
four different depths within the SOBP region as well as at 5 cm depth in entrance 
region. The measurements were performed using either EDR2 film (Carestream Health, 
Inc, NY) or a MatrixxPT ion chamber array device. Plans were selected to cover field 
sizes of 5 x 5 to 20 x 20 cm2, ranges 8.5 to 32 cm, and SOBP widths 5 to 22 cm. 
Overall, more than 60 profile measurements were performed.  The planned and 
measured profiles match well at both the shoulder and penumbra regions. The 
maximum deviation in full width half maximum was less than 1 mm. Figure 22 shows 
the profile comparison for four SOBP cases. 
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Figure 21: Ratio of measured over calculated point doses at the central axis for various 
plans given in Table 3 as a function of (a) Range, (b) Depth, and (c) Field Area 
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2.3.7. TG-119 QA Plans 
The goal of these tests was to test the overall accuracy of the spot scanning 
planning and delivery system. 
2.3.7.1. Test Plan P1: Multi Target 
A three beam arrangement consisting of left lateral, vertex and anterior beams 
was used to optimize the three given dose levels. The planning system was successful 
in finding a solution that met all the given treatment plan goals as outlined in TG-119. 
The quality assurance of the plan consisted of the beam by beam delivery and 
verification using the 2D MatrixxPT array. Two to three planes were selected for each 
beam and analyzed for gamma index. The results are given in Table 5. The gamma 
pass rate for all the planes was greater than 94.5% at 3%/3 mm criteria.  
 
Figure 22: Comparison of measured and planned lateral dose profiles for four SOBP 
fields, (i) Range =8.5 cm, SOBP width= 1 cm, Profile Depth =8 cm; (ii) Range =13 cm, 
SOBP width= 5 cm, Profile Depth =10.5 cm; (iii) Range =20 cm, SOBP width= 10cm, 
Profile Depth =17.5 cm; and (iv) Range =32.5 cm, SOBP width= 10 cm, Profile Depth 
=23.5 cm. 
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2.3.7.2. Test Plan P2: Mock Prostate 
The prostate target was irradiated by using two opposed lateral beams. All the 
treatment planning goals provided in TG-119 were met. The QA was done at two 
different depths for each beam i.e. at the proximal side of SOBP at 10 cm depth and in 
the middle of the SOBP at 15 cm depth. Table 5 shows the results of the gamma index 
analysis. The minimum gamma index for all the planes was 99.2% using the 3%/ 3 mm 
criteria.  
2.3.7.3. Test Plan P3: Mock Head/Neck 
The mock head and neck target was planned using two beams: left lateral and 
vertex. All the constraints given in TG-119 were met during the plan optimization. Three 
planes, one in proximal region and other two in the middle of the SOBP were picked for 
beam by beam quality assurance. The results of the gamma index analysis are given in 
Table 5. Also shown is the gamma analysis for vertex beam at a plane 10 cm depth in 
Figure 23. The minimum gamma index for all the planes was 99.7% using the 3%/ 3 
mm criteria.  
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Figure 23: Gamma analysis corresponding to vertex beam of H&N plan at 10cm depth. 
 
2.3.7.4. Test Plan P4: C Shape Target (easy and difficult constraints) 
The first variant for this mock target case as given in TG-119 has relatively easy 
dose optimization constraints. The second variant has more difficult constraints with the 
idea of pushing the planning system harder. A three beam arrangement consisting of a 
left lateral, right lateral, and an anterior beam was used to optimize the desired dose 
levels. All the goals given by TG-119 were met for the target with easy constraints. The 
second variation with more stringent goals had two constraints that could not be met 
even after successive optimizations. The structures with violations are Core (5% of the 
volume to receive no more than 1000 cGy, achieved value = 23.3%) and CShape PTV 
(95% volume to receive at least 5000 cGy, achieved value = 84.1%). Two to three 
planes were selected for each beam for quality assurance. The results of the gamma 
index analysis are given in Table 5. The minimum gamma index for all the planes (both 
the easy and difficult constraints) was 92.8% using the 3%/ 3 mm criteria.  
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Table 5: Results of the field by field gamma index (GI) with 3%/3mm criteria at given 
depths for various targets outlined in TG-119. Only dose values greater than 10% of 
maximum were evaluated for GI. 
 
2.4. Discussions 
The clinical implementation of the RayStation proton pencil beam scanning 
system has been presented. The beam modelling for pencil beam in RayStation 
requires the IDDCs (or Bragg peaks) in relative units. In order to measure these Bragg 
peaks with a scanning ion chamber, a reference signal is required. The positioning of 
the reference detector in the beam path is difficult due to the small size of the spot. One 
way to mitigate this issue is to get a reference signal directly out of the nozzle MU 
chamber. 
A trend can be seen in Figure 24 where the discrepancy between measured and 
calculated doses increases with the field size for higher energy. We found that the 
RayStation planning system underestimates doses for beams that have field 
sizes>15x15 cm2 and energy >218 MeV. The maximum differences for some points 
were found to be as much as 4.5%. Most of these beams are rarely used in the clinic. 
The higher differences for larger fields and higher energies may be attributed to a 
couple of reasons: (i) The measurements of the IDDCs using an 8 cm Bragg peak 
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chamber will not account for any charge in the low dose region that is further than 4 cm 
from the central axis (16, 37-39), and (ii) the inability of the pencil beam algorithm to 
accurately account for the low dose region produced around the central spot which is 
called “nuclear halo.”  Although a second Gaussian is used to model the nuclear halo, it 
may not be enough to model the low dose tails that are produced farther from the 
central axis. As the field size increases, this effect gets compounded by the addition of 
low dose tails at the central axis. Since the SOBP plans are basically composed of 
many single layers with different weights, the dose differences from unmodified single 
layers are propagated to the complex inversely modulated SOBP plans. The efficiency 
of an 8 cm BP chamber was estimated using the open source, highly validated GATE 
(Geant4 Applications for Tomographic Emission) code (40). The Bragg peak 
corresponding to 226 MeV cm was simulated for two scenarios: (a) charge collected in 
8 cm diameter disc to simulate the BP chamber, and (b) charge collected in 40 cm slab 
to account for low dose tail (Figure 24). The maximum loss of charge was -8.3% at 21 
cm depth. Although, it is very desirable to have a chamber bigger than 8 cm for IDDC 
measurement, at the time of our commissioning no bigger chamber was available. Even 
though our measurements were done with 8 cm, the validation results show that the 
performance of the TPS is clinically acceptable under most of the conditions. An 8 cm 
BP chamber was also used for commissioning purposes by Fracchiolla et al. (41). 
 
Commissioning of range shifters is necessary to enable the treatment of shallow 
targets. In the version 4.5 of RS, whenever a range shifter is added to the beam path, 
the range shifter and the physical air gap are considered part of the patient geometry. 
The dose calculations are started at the upstream surface of the range shifter. The 
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result is a large inhomogeneity (air gap) in the beam path that is not handled well in RS 
version 4.5. Discrepancies as large as 8% were seen at the shallow depths for the 
thicker (7.5 cm WET) range shifter. One possible solution is to commission a separate 
beam model from spot profiles and IDDCs measurements made with the range shifter 
in place. This was not done as RS was developing an improved analytical as well as a 
MC dose algorithm. 
Figure 24: GATE Simulation illustrating loss of charge due to 8 cm Bragg Peak 
Chamber. 
 
Prior to the clinical release of the TPS, an independent verification of dose-MU 
calibration was performed by a physicist not involved in the commissioning process. 
Later, calibration check OSLDs from the Imaging and Radiation Oncology Core (IROC, 
Houston, TX) were irradiated and the output was determined to be within 1%. In 
January 2015, a site visit was undertaken by an IROC team to credential the use of 
proton therapy in NCI-funded clinical trials at SCCA-PTC. As part of the credentialing 
process, various anthropomorphic phantoms (proton head, proton lung, proton prostate, 
and proton liver) were irradiated. After the successful irradiation of phantoms, site visit, 
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and calibration check TLD, the SCCA-PTC completed the IROC approval process and 
obtained the credentialing in April 2015. 
The commissioning and verification methodology presented in this study can be 
used as a reference guide by upcoming proton therapy centers.  Very often, the 
capabilities of a newly acquired TPS in terms of dose calculation accuracy and 
limitations are not known before the commissioning process. Our study will aid such 
centers and has a potential to reduce the variability of the proton PBS commissioning. 
This could further standardize the RT dose reporting in future multi-center trials utilizing 
pencil beam scanning. 
2.5. Conclusions 
A successful clinical implementation of RayStation TPS for pencil beam planning 
was performed. The beam model data requirements were obtained from the RayStation 
physics manual. Measurements were performed using a variety of detectors such as 
parallel plate ion chambers, 2D ion chamber arrays, Bragg peak chamber, 2D high 
resolution scintillation imager, and radiographic film. All the beam data was packaged 
and sent to a RayStation team for beam modeling process. The resulting beam model 
was put to a series of tests that involved verification of point doses, PDDs, profiles, and 
doses in patient specific plans. Tests were also done to study the variation of beam 
output with the field size. The results of the verification process were found to be 
adequate for clinical release of the TPS. The limitation of the planning system to 
accurately predict the doses for larger field and larger ranges were also noted. It was 
deemed that the cases exhibiting results outside the tolerances were less clinically 
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relevant. Subsequent upgrades to the planning system were anticipated to address 
some of the limitations.  
The validation of analytical pencil beam algorithm was performed by 
comprehensive set of measurements in a water phantom. The accuracy of analytical 
pencil beam algorithm in determining accurate doses in water is no guarantee that 
algorithm will also be able to perform adequately in non-homogenous media. In non-
homogenous media, additional consideration due to change in density and atomic 
composition of materials become important and need to be considered in the dose 
calculations. In next chapter, we have presented the results of validation of 
RayStation's Monte-Carlo algorithm in both homogenous and non-homogenous media. 
We have also contrasted the performance of analytical pencil beam algorithm to 
RayStation’s Monte-Carlo algorithm for a variety of test cases. 
53 
 
 
 
CHAPTER 3 DOSIMETRIC EVALUATION OF A COMMERCIAL PROTON 
SPOT SCANNING MONTE-CARLO DOSE ALGORITHM: 
COMPARISONS AGAINST MEASUREMENTS AND SIMULATIONS 
 
3.1. Introduction 
Accurate dose calculation is paramount in radiation therapy so that clinicians can 
make the most informed decision during treatment planning. Tumor control probability 
(TCP) and normal tissue complication probability are steep functions of absorbed dose 
in certain disease sites and therefore dose calculations with an accurate algorithm are 
necessary to plan treatments within a narrow therapeutic window. Most proton dose 
calculation algorithms can be assigned to two classes: analytic and Monte Carlo (MC). 
Analytical methods such as pencil beam algorithms (22-24, 42) involve the transport of 
energy fluence through infinitesimally narrow beams. Each beam is divided into many 
pencil beams that are ray-traced individually through the medium. For each pencil 
beam, the particles undergo elastic and inelastic interactions based on proton energy 
and the medium of interaction. The dose at any point is found by summing the 
individual contributions from all pencil beams. MC algorithms, on the other hand, track 
individual particles where for each interaction, energy loss and scattering effects are 
calculated through the random sampling of cross section data (43).  
Most of the clinical dose calculations for proton spot scanning are carried out 
using pencil beam analytical algorithms as they are commercially readily available and 
provide fast and efficient dose calculations. However, analytical algorithms do not 
provide accurate dose calculation in heterogeneous media as multiple elastic Coulomb 
scattering as well as elastic and inelastic nuclear interactions can only be approximated 
in these algorithms (44).  Analytical algorithms model patients as a stack of semi-infinite 
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layers - i.e. assuming materials encountered by the central axis of each pencil beam to 
be laterally homogenous slabs along the depth. This approximation is a major limitation 
in complex geometries where lateral inhomogeneities are not accurately accounted.  
MC algorithms do not suffer from these drawbacks as they track individual particle 
trajectories through material and therefore can provide accurate dose calculation in 
both homogenous and heterogeneous media. Several studies (45-52) have shown the 
importance of proton dose calculation using MC for certain sites. Scheumann et al. (48) 
assessed the impact of analytical dose calculation algorithms for various sites and 
found TCP differences of up to 11% for lung, head and neck and prostate patients. 
Another study by Grassberger et al. (49) showed an under-dosing of the CTV 
exceeding 5% for small fields in lung. Additionally, for larger lung tumors penumbra 
broadening was observed resulting in higher normal lung V5 and V10 values. These 
studies underline the importance of using MC dose calculations for clinical use in proton 
spot scanning.  
There are many codes and packages available for MC calculations for protons 
including Geant4 (53, 54), MCNPX (55), FLUKA (56), and PHITS (57). In addition, there 
are toolkits and extension packages, such as Tool for Particle Simulation (TOPAS) (58), 
Geant4 Application for Tomographic Emission (GATE) (40), Pre-calculated Monte Carlo 
(PMC) (59), and MC-Based treatment planning tool (MCTP) (60), that wrap around one 
of these MC codes to provide an environment suitable for running radiotherapy MC 
simulations. However, most of these packages are research based applications and do 
not have FDA approval for clinical use. Due to their research-based nature, these 
packages do not offer all the features that are expected from commercial treatment 
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planning system (TPS) such as an intuitive graphical user interface, ability to import and 
export plans, and ability to visualize patient anatomies in a user friendly manner. In 
addition, the calculations are often too slow for routine treatment planning even with the 
aid of dedicated high performance computing resources. Recently, RaySearch 
Americas Inc. (NY) introduced a new commercial solution RayStation ver 6.0 (RS6) for 
MC treatment planning intended for clinical use and equipped with all the features 
expected from a modern TPS. RS6 provides users with the choice of two algorithms for 
dose calculation: analytical pencil beam algorithm ver 4.0 (RS-PBA) and a proprietary 
Monte-Carlo algorithm ver 4.0 (RS-MC). Both dose algorithms may be used to drive 
inverse plan optimization and final dose calculation. According to the manufacturer, RS-
MC provides fast and accurate dose calculations for routine use in a clinical setting. 
However, the process of implementing a fast and efficient MC dose engine can often 
result in approximations for physical processes that could compromise the desired dose 
calculation accuracy. Accordingly, this report presents the validation of RS-MC using 
measurements performed in homogenous and heterogeneous phantoms, and 
simulations performed in the validated GATE MC package.  
Our work for validating RS-MC is divided in the following phases: 
• Developing a beam model (G-MC) for our gantry in the GATE MC toolkit using 
measured beam data. Validation of G-MC is carried out against measurements 
performed in a water phantom.  
• Comparison between measurements, G-MC, RS-MC, and RS-PBA in homogenous 
and simple slab heterogeneous geometries for a variety of test cases. 
• Comparison between RS-MC and RS-PBA in an anthropomorphic phantom.  
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3.2. Methods and Materials 
3.2.1. RayStation Treatment Planning System 
RS6 provides options for calculating doses for pencil beam scanning plans with 
either RS-PBA or RS-MC. The RS-MC dose engine does not require any separate 
commissioning and the same beam model that is used for RS-PBA dose calculation 
can be used for MC dose calculations. Our previous work (61) described the clinical 
commissioning of RayStation ver 4.51 for pencil beam dose algorithm. The 
commissioning of ver 6.0 is same as ver 4.5. All of the treatment planning calculations 
in this work were performed with a 1 mm isotropic grid. For calculations using RS-MC, 
the doses were calculated to have <1% statistical uncertainty. 
3.2.2. SCCA Proton Therapy System 
Measurements were performed in a proton gantry at the Seattle Cancer Care 
Alliance Proton Therapy (SCCA-PT) center. SCCA-PT is a four room center (34) with 
IBA Proteus Plus (Ion Beam Applications, Louvain-Neuve, Belgium) cyclotron and has 
capabilities to deliver spot scanning and uniform scanning beams. The spot scanning 
gantry offers full 360 degree rotation and provides a proton beam with continuous range 
in water from 7.5-32 cm (proton energies 98.5-226 MeV). The maximum available field 
size at the isocenter plane is 40 X 30 cm2. 
3.2.3. Development and Validation of G-MC Beam model 
A beam model was commissioned in G-MC based entirely on measured beam 
properties at nozzle exit avoiding the modeling of any nozzle components as described 
here (62). The nozzle exit was placed 40 cm upstream from the isocenter plane in the 
simulation (Figure 25). 18 discrete energies (61) with a spacing of 7.5 MeV were 
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selected from the continuum of available energies 98.5- 226 MeV. For MC simulations, 
the recommendations provided by Grevillot et al (63) for different GEANT4 settings for 
proton particle therapy energy range were used. As recommended, 1 mm was used for 
the range cut (production threshold for secondary particles after EM interactions) and 
maximum allowable step size value (distance to next interaction). The pre-calculated 
EM tables for mean free path, restricted stopping power, and range were set to 20 bins 
per decade to accurately describe the EM interactions.  The physics models were 
implemented using the pre-defined physics builder mechanism and included binary 
cascade along with option 4 for electromagnetic interactions. The ionization potential for 
water, important for accurate range modeling, was set to 75 electron volts based on the 
recommendations of ICRU reports 37 (64) and 49 (8). The voxel size was set to 1 mm3 
isotropically.   
G-MC provides a mechanism to create a pencil beam source model by means of 
including all beam related parameters in a single “source-properties” file (62). The 
source-properties file has –x and –y direction polynomials related to spot size, energy 
spread (expressed as percentage of mean energy), and angular spread (beam 
divergence) as a function of energy. In addition, the source-properties file also needs 
information about the position of the scanning magnets and assumed nozzle exit 
position from the isocenter. 
58 
 
 
 
 
Figure 25. The G-MC model for the gantry beam at the SCCA Proton Therapy Center 
was created in GATE. The model, based on measured beam properties, started at the 
nozzle exit i.e. 40 cm upstream from isocenter. 
 
The lateral profile of a single spot incident along the central axis for each of the 
18 energies was measured using a two dimensional Lynx scintillator detector (IBA 
Dosimetry, Schwarzenbruck, Germany). These measurements were made at two 
planes i.e. at nozzle exit (40 cm upstream) and isocenter. The lateral spot profiles were 
fit to a 2-D Gaussian function and standard deviation values (spot sigma) were obtained 
for –x and –y directions. The enlargement of the spot sigma with the downstream 
distance from nozzle exit was used to calculate angular spread for all 18 energies. Six 
degree polynomial functions were obtained for variation of spot sigma and angular 
spread with energy and resulting coefficients were placed in the source-properties file. 
Integrated depth doses (IDDs) were obtained using the 8 cm Bragg Peak ionization 
chamber (PTW Inc., Freiburg, Germany) and a PC Electrometer (Sun Nuclear Corp., 
Melbourne, FL) with a single spot incident at the central axis. The IDDs were scanned 
with a 1 mm resolution.  Simulations were carried out in G-MC using the same 
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geometry and beam set up with preliminary values of mean energy and energy spread. 
The mean energy was adjusted until the error in R80 (distal depth corresponding to 
80% of maximum) depths for simulated and measured values was less than 1 mm. 
Similarly, the energy spread was adjusted in small increments to minimize the local 
error between the simulated and measured IDDs to less than 2% at any point. The 
measured and simulated IDDs were normalized to area-under-the-curve and analysis 
for dose-to-peak and mean point-to-point dose differences were performed as 
described here (41, 62). The final values of energy spread versus energy were fit to a 
six degree polynomial and resulting coefficients were placed in the source-properties 
file. 
All the G-MC simulations were performed on a commercial MacBook Pro (Apple 
Inc., Cupertino, CA) laptop computer with 2.2 GHz quad-core Intel Core i7 processor, 
16 GB of 1600 MHz DDR3L onboard RAM running the OS X Yosemite version 10.10.4 
operating system. The G-MC doses were calculated for <2% statistical uncertainty. 
3.2.4. Comparisons in Homogenous Media 
Measurements were carried out in a water phantom for three different spread out 
Bragg peak (SOBP) combinations with field size of 10 x 10 cm2: (i) SOBP1: Range=13 
cm, Modulation = 5 cm, (ii) SOBP2: Range= 20 cm, Modulation= 10 cm, (ii) SOBP3: 
Range = 25 cm, Modulation=10 cm. These SOBPs were generated by inversely 
optimizing dose to box targets in the planning system using the RS-PBA algorithm. The 
beams were made perpendicular to the simulated water phantom without any beam 
modifiers (i.e. range shifter) to deliver uniform dose to the box targets. Once a SOBP 
was optimized, the plan was copied and re-calculated using the RS-MC algorithm. The 
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spot map and energy information of each layer was extracted from RayStation and 
converted to a G-MC compatible file. Finally, depth doses were calculated in G-MC by 
simulating the measurement geometry. 
   A four-way comparison of depth doses and lateral profiles was made 
between measurements, G-MC simulations, RS-MC, and RS-PBA. The depth dose 
measurements were conducted using a commercial multi-layer ionization detector 
(MLIC) (Zebra, IBA Dosimetry, Schwarzenbruck, Germany) that has 180 detectors and 
depth dose resolution of 2 mm. A tolerance of +/-3% was allowed for depth dose 
comparison between measured and calculated (RS-MC, RS-PBA or G-MC) for all 
points except at the distal edge. The distal edge was evaluated by comparing the range 
at R80 depth of measured versus calculated. The range was considered acceptable if 
the deviation from measured was less than 1 mm. The lateral profiles were measured 
at four different depths for each SOBP using the MatrixxPT detector (IBA Dosimetry, 
Schwarzenbruck, Germany). The calculated profiles were compared to measurements 
(reference dose) through a gamma index analysis (65) with a dose tolerance (DT) of 
3% and distance-to-agreement (DTA) of 3 mm.  
Range shifters are very common for proton spot scanning when treating a target 
that lies shallower than the smallest available range. Current analytical pencil beam 
algorithms are not able to accurately account for perturbations in dose distributions 
distal to the range shifter. RS-PBA accounts for a range shifter by assuming the range 
shifter and air gap to be part of the patient outline (66), where ray tracing starts at the 
upstream surface of the range shifter. This results in geometry with a very large 
inhomogeneity. Currently, the RS-PBA algorithm does not formally handle the transport 
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of secondary low energy protons that result from interactions in a range shifter. Since 
these are low energy protons, there is a greater dose discrepancy at shallower depths 
(<3 cm) when large air gaps (>10 cm) are used. In order to test the impact of the air gap 
between the range shifter and patient geometry, SOBP2 was measured at two different 
air gaps: 5 and 31.5 cm. A range shifter with water-equivalent-thickness (WET) of 7.5 
cm (Base material = Acrylic, Physical Thickness = 6.5 cm) was inserted in the beam 
path and measurements were made using the MLIC detector. The measurement 
geometry was produced in G-MC and RS6 TPS to obtain depth doses at the central 
axis. Local dose differences between calculated and measured depth doses were 
analyzed. 
For many clinical sites such as head and neck, breast and brain, use of oblique 
beams with a range shifter is necessary for sparing of critical structures. Generally, 
patient specific QA is performed by orienting the beam angles to have a normal 
incidence to a phantom. Unfortunately, this process could give a false sense of 
assurance in a treatment plan as some dosimetric errors are due to an inability of the 
analytical dose calculation algorithm to model obliquity, and will be missed. Analytical 
algorithms split a broad proton beam into many small pencil beams that are traced 
individually through a material. At oblique angle incidence, the protons will traverse 
different thicknesses of material within each pencil beam. However, analytical 
algorithms assume a constant thickness of material corresponding to the central axis of 
pencil beam. Thus, one could expect to see changes in the spectrum of proton energy 
as the beam travels through the medium, potentially impacting the shape of the distal 
edge. We created a test using SOBP2, range shifter of 7.5 cm, air gap 12 cm (at central 
62 
 
 
 
axis), to be incident on water phantom at 45 degrees (Figure 26). The depth doses at 
the central axis were calculated using G-MC/RS-PBA/RS-MC. Measurements were 
performed using the MatrixxPT detector in solid water at several depths with a 45 
degree angle of incidence.  
3.2.5. Comparisons in Heterogeneous Media 
The goal of this test was to evaluate the accuracy of dose calculations by RS-
MC/RS-PBA/G-MC due to interfaces created by placing bone or lung slabs in a water 
phantom. Figure 27 shows the phantom set up for these measurements. The bone or 
lung slab (CIRS Inc., Norfolk, Virginia) was placed at 15 cm depth in a water phantom 
to align the edge with the central axis of the beam. This was done to have only half of 
the SOBP beam to go through the heterogeneity so that an interface of lower and 
higher protons can be formed at the distal end of the beam. Since analytical algorithms 
use central axis approximation where the material at any depth is assumed to be 
laterally infinite, the range of proton pencil beam at the sharp interface due to the 
inhomogeneity is not properly handled. Due to this limitation, the calculated doses using 
analytical algorithms may exaggerate hot and cold spots in some areas near the central 
axis towards the distal edge of the beam. The atomic composition of the slabs was 
obtained from the manufacturer (Table 6) so that equivalent materials can be created in 
RS-TPS and G-MC.  
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Figure 166. Depth doses at central axis were obtained for SOBP2 with oblique 
incidence (45 degrees). An acrylic range shifter with physical thickness of 6.5 cm 
(WET=7.5 cm) was placed at an air gap of 12 cm. 
 
 
Figure 27. Inhomogeneous phantom with a bone or lung material equivalent slabs were 
created by placing slabs in a water phantom. The slab was positioned at 15 cm depth 
such that edge of the slab was aligned with the central axis of the beam. SOBP2 
(Range= 20 cm, M= 10 cm) was used for measurement and simulations. The 
measurement was performed at the distal edge of the beam. 
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Table 6. Elemental Composition of bone and lung slab was obtained from 
manufacturer. Published with permission from CIRS Inc. 
 
 
Measurements and simulations were performed by using the SOBP2 beam. 
Dose profile measurement at the distal edge interface i.e. 20 and 21.5 cm for bone and 
lung respectively, were made using the microDiamond detector (Type 60019, PTW-
Freiburg, Germany) and PC electrometer (Sun Nuclear Corp., Melbourne, FL). The 
MicroDiamond detector has been shown to be independent of dose rate and proton 
energy (67) and due to its small size, introduces a minimum amount of perturbation. 
Qualitative analysis was performed using the one dimensional gamma index analysis 
(tolerance: Dose =1% to 3% and DTA=1 mm) between measurement (reference dose) 
and GATE-MC/ RS-MC/RS-PBA. 
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Figure 28. Axial, sagittal and coronal planes of the AR Phantom section with assumed 
cylindrical target (red shaded). A vertex beam (orthogonal to AR slices) was used to 
deliver uniform dose to the target. 
 
3.2.6. Comparisons in Anthropomorphic Phantoms 
In order to test the performance of dose calculation algorithms in clinical 
conditions, an Alderson-Rando (AR) (Radiology Support Devices, California, US) 
phantom section with heterogeneous anatomy (figure 28) was used for planning and 
measurements. The phantom section encompasses various tissues such as lung and 
mediastinum where inhomogeneities run parallel to the beam direction. Computed 
tomographic (CT) images of phantom were obtained using a GE Optima CT580 
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scanner (GE Healthcare, Waukesha, WI) with 120kVp and 1.25 mm slice thickness. 
The CT images were transferred to the RayStation treatment planning system for 
contouring and treatment planning. A quasi cylindrical target with a 10 cm diameter and 
9 cm length was created in the phantom (figure 28). A treatment plan with a single 
beam incident orthogonally to slice direction was used to deliver 40 Gy (RBE) uniform 
dose in 10 fractions to the target. The beam direction was chosen to have lateral 
interfaces between lung and normal tissue that may not be accurately accounted for by 
analytical dose calculation algorithms. The plan was optimized using RS-PBA with a 1 
mm grid size in –x, -y, and –z directions. The same plan was copied and also calculated 
using the RS-MC algorithm with a statistical uncertainty of <1%. The plan was 
transferred to the system Mosaiq (Impac Medical Systems, Elekta, CA) to be delivered 
to the AR phantom. Gafchromic EBT3 film (Ashland Inc., NJ) was placed between each 
slice of the AR phantom. The phantom was then placed on the couch to align the 
treatment isocenter with lasers. The irradiated films were scanned 24 hours post 
exposure on a flatbed scanner (Epson Expression 11000XL, Epson America Inc., 
California, USA) using 72 pixels per inch of resolution and landscape orientation. The 
digitized films were analyzed using the commercially available DoseLab software 
(Mobius Medical Systems, TX, US). A control film that was similarly handled but not 
exposed was also scanned to obtain net optical density using the red channel. The film 
doses were compared to doses calculated by RS-MC and RS-PBA algorithm using 
gamma index analysis (various DT and DTA tolerances). The dose profiles after every 
AR phantom slab were also measured using the MatrixxPT (IBA Dosimetry, 
Schwarzenbruck, Germany) detector. The doses from MatrixxPT detector were used to 
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scale the corresponding Gafchromic film doses at the same depth to obtain absolute 
doses needed for gamma index analysis. 
3.3. Results 
3.3.1. Gate MC Beam model validation 
The lateral spot profiles expressed in terms of sigma values at the isocenter and 
nozzle planes are shown in figure 29(i). The variation of energy spread as a function of 
energy is shown in figure 29(ii). Our value of energy spread is in agreement with 
reported values in literature (41, 62). The maximum difference in range (as described 
by R90) between simulated and measured IDDs was -1.0 mm (proton beam of 218.5 
MeV) and the average was less than 0.3 mm. The mean point-to-point difference 
between simulated and measured IDDs when normalized to area-under-the-curve was 
always less than 1.5%. In addition, the maximum difference at dose-to-peak for all 18 
energies was -2%. The detailed results are shown in figure 30(i). These results confirm 
that the performance of the G-MC model is acceptable for benchmarking the RS-MC 
and RS-PBA algorithms. An example of simulated and measured IDD with the point-to-
point error along the depth dose for energy of 226 MeV proton beam is shown in figure 
30(ii).  
The maximum difference in measured and modeled spot profiles at the isocenter 
plane is 0.12 and 0.09 mm for –x and –y directions with average differences of 0.05 and 
0.03 mm in –x and –y directions respectively. 
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(i) 
 
(ii) 
Figure 29. (i) Variation of spot sigma with energy. The spot sigma values at the nozzle 
entrance i.e. 40 cm upstream of isocenter are shown for –x direction (blue solid 
squares) and –y direction (red solid squares). The spot sigma values at the isocenter 
plane are shown for –x direction (blue solid triangles) and –y direction (red solid 
triangles). (ii) Variation of percentage energy spread as a function of proton beam 
energy.  
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(i) 
 
(ii) 
Figure 30. (i) Performance evaluation of G-MC model against measurements. The 
simulated and measured IDDs were analyzed for mean point-to-point difference (red 
solid squares), range errors (green solid triangles), and dose-to-peak differences (blue 
solid diamonds). (ii) An example of IDDC for proton beam energy 226 MeV: simulated 
(blue dashed line), measured (solid red line), and local dose differences in percentage 
(green solid squares). The IDDs were normalized to area-under-the-curve. 
 
3.3.2. Comparisons in Homogenous media 
The depth dose comparison for SOBP1-3 between measurement and RS-
MS/RS-PBA/G-MC is shown in figure 31. A spread of +/-3% from the measured is 
shown with the dotted lines. All the points for RS-PBA, RS-MC and G-MC are within 3% 
of the measured except at the distal edge. The accuracy of distal edge was measured 
by R80 values and was within 1 mm for all cases (Table 7). Table 8 shows the gamma 
results of measured versus RS-MC/RS-PBA/G-MC lateral dose profiles for all three 
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SOBPs at four different depths. The average gamma index value of RS-MC, RS-PBA, 
and G-MC versus MatrixxPT measurement averaged over all the measured planes was 
97.2, 97.3, and 98.9% respectively.  
 
Figure 31. Comparison of percentage depth doses between measurement (solid red), 
G-MC (dotted blue), RS-PBA (solid green circles), and RS-MC (solid purple triangles). 
Top: SOBP1, Range 13 cm, Modulation 5 cm. Middle:  SOBP2, Range 20 cm, 
Modulation 10 cm. Bottom: SOBP3, Range 25 cm, Modulation 10 cm. Also shown are 
error bars corresponding to +/-3% of measurement (dotted black lines). 
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Table 7. Difference in R80 range from measurement for G-MC, RS-MC and RS-PBA 
for SOBPs1-3. Results are given in mm.  
 
Table 8. Gamma index analysis results for SOBPs1-3 against measurement at four 
different depths using tolerances: DT= 3%, and DTA= 3mm. 
 
 
The depth doses and corresponding percentage errors for SOBP2 with a range 
shifter are shown in figure 32. At 5 cm air gap, the maximum local dose error from 
measured was 2.3, 1.3 and 2.0% for RS-PBA, RS-MC and G-MC respectively. At an air 
gap of 31.5 cm, all the points for RS-MC and G-MC were within +/-3% of measurement. 
However, RS-PBA, over-estimated the dose by as much as 10% at shallow depths 
(<0.5 cm). The discrepancy between measured and calculated decreased with depth 
and reduced to less than 3% at a depth of 5cm.  
Figure 33 shows the comparison of depth doses when SOBP2 is incident at 45 
degree angle. For dose points measured in the flat SOBP area and proximal region of 
the SOBP, both RS-MC and G-MC had acceptable agreement with measurement with a 
maximum error of -1.4% and -2.3% respectively. For RS-PBA, up to 6.5% error was 
seen from measurement in the SOBP area and dose points on the proximal side of the 
SOBP. Greater discrepancy between RS-PBA and measurement were found in the 
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distal penumbra region. Distal penumbra (distance between points corresponding to 
80% and 20% of maximum dose at the distal fall-off) comparisons between 
measurement and RS-PBA/RS-MC/G-MC were performed (Table 9). Both RS-MC and 
G-MC were able to predict distal penumbra within 2 mm of the measured. For RS-PBA, 
the distal penumbra increases as much as 5 mm. 
Figure 32. Evaluation of SOBP2 with range shifter of 7.5cm WET at two different air 
gaps, 5 cm (top) and 31.5 cm (bottom).  Comparison is shown for measurement (red), 
G-MC (dotted black), RS-MC (solid green), and RS-PBA (solid blue). The local error 
between measurement and G-MC (dashed black), R-MC (dashed green), RS-PBA 
(dashed blue) is shown. 
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Figure 33. Depth dose comparison at the central axis for SOBP2 with a range shifter of 
7.5 cm WET. The beam was incident at 45 degrees on water phantom. Measurements 
(solid red squares) were performed by a MatrixxPT device. The depth doses generated 
by RS-MC (solid green line), RS-PBA (solid blue line), and G-MC (dotted black) are 
shown. The local error between measurement and RS-MC (solid green square), RS-
PBA (solid blue squares), G-MC (solid black squares) is shown. 
 
Table 9. Error in distal fall-off for SOBP2 incident at 45 degrees on water phantom  
 
 
3.3.3. Comparisons in Heterogeneous media 
Figure 34 shows the 2D dose profiles corresponding to the center of the 
phantom for a bone slab.  The line dose profiles measured at the distal edge with the 
microDiamond detector are shown for both bone and lung slabs in figure 35. Both G-
MC and RS-MC algorithms were able to predict accurate dose at the interface. RS-PBA 
algorithm showed broadening of dose fall-off effectively showing reduction in dose on 
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the bone (or lung slab) side and increase in dose on the opposite side of the slab. 
Using the DT=1% and DTA=1 mm criteria for 1-dimensional gamma index analysis 
between measured and calculated, the pass rates were 100% for G-MC for both lung 
and bone slabs. In case of R-MC, the pass rates were 100% and 94.4% for bone and 
lung targets respectively. The gamma index was <30% for lung and bone slabs for RS-
PBA. Full results are given in Table 10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Two dimensional dose profiles obtained at the center of field obtained using 
RS-MC (left), G-MC (center), and RS-PBA (right) dose calculation algorithms. The bone 
slab was placed at 15 cm depth to align with the central axis. The microDiamond line 
dose measurements (as shown by solid white line) were performed at 20 cm for bone 
slab and 21.5 cm for lung slab. 
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Figure 35. One dimensional dose profiles at the distal side of the inhomogeneity (see 
figure 27). The measurements (black dotted) were performed by a microDiamond 
detector. The calculated dose profile are G-MC (blue dash dot), RS-MC (red dash), and 
RS-PBA (green solid). Panel A: 2 cm bone slab at 15 cm depth, Panel B: 2 cm lung 
slab at 15 cm depth.  
 
 
 
 
 
 
 
3.3.4. Comparisons in Anthropomorphic Phantoms 
The qualitative results of the 2-D dose profiles acquired with Gafchromic film 
after every slice of the AR phantom along with RS-MC and RS-PBA measurements are 
shown in figure 36. There was good agreement between RS-MC and film measurement 
at all depths while RS-PBA could not reproduce features in the dose profile at depths 
closer to the distal edge. The –x and –y 1-D dose profiles at depth 15 cm were plotted 
Table 10. Results of 1-D  gamma index analysis comparing microDiamond 
measurement to G-MC or RS-MC or RS-PBA dose calculation algorithms using 
various DT and 1 mm DTA tolerance.  
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in the center of the target for measurement, RS-MC, and RS-PBA (figure 37). It can be 
seen that the RS-PBA algorithm maintained a high degree of dose uniformity in target 
and failed to account for dose perturbations resulting from lateral inhomogeneities such 
as interfaces formed by lung/heart/ breathing air ways and holes in the AR phantom. 
  The results of the gamma index analysis between measured and RS-MC/RS-
PBA are shown in Table 11. The gamma index for RS-MC was greater than 90% 
(3%/3mm) at all depths except for the most distal plane which had a gamma index of 
74.3%. For RS-PBA, 4 of 7 planes had gamma indexes less than 90% while the most 
distal layer had a gamma index of 45.7%. It should be noted that the most distal plane 
was outside of the high dose region (and also target) and positioned in the high dose 
gradient of the distal edge.  
 
Figure 36. Dose planes obtained using RS-PBA (top), Gafchromic film (center), and 
RS-MC (bottom) after every slice of mediastinum section of AR phantom as shown in 
figure 28.  
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Figure 37. One dimensional dose profiles in –x and –y direction corresponding to depth 
15 cm in mediastinum AR phantom. Shown are measurement (solid red), RS-MC 
(dotted blue), and RS-PBA (solid green). 
 
Table 11. Results of 2-D gamma index analysis comparing RS-MC or RS-PBA dose 
calculations to measurements in an anthropomorphic mediastinum lung phantom. 
 
 
3.4. Discussions 
Accurate dose calculations are an essential tool for optimal patient treatment in 
radiation therapy. Currently, pencil beam analytical algorithms that do not accurately 
account for inhomogeneities are the standard of care for treatment planning in proton 
therapy. The limitations of dose calculation algorithms may not be readily apparent in 
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routine clinical workflow as most of the patient-specific quality assurance 
measurements are made in the homogenous phantoms with normal incidence. This 
method does not check the performance of the dose calculation algorithms under 
clinical conditions where a proton beam traverses through a variety of tissues often at 
oblique incidence, resulting in very different scatter conditions. ICRU 24 (68) 
recommended that dose delivery accuracy to be +/-5% to a target volume if the 
objective of treatment is eradication of the primary tumor. Use of analytical algorithms 
for sites where a large amount of inhomogeneity is expected could result in dose 
inaccuracies in excess of 5% to parts of the target volume. The previous investigation 
by Grassberger (49) showed up to 5.6% overestimation at the center of a lung target 
when using the analytical dose calculation algorithm. Using MC, the dose difference 
was reduced to 1.6%. Similarly Schuemann (48) also showed up to 5% dose difference 
for complex geometries of H&N, and lung when using an analytical dose calculation 
algorithm. These studies concluded that the integration of MC into routine clinic use is 
vital for improvement of treatment quality for complex geometrical sites. 
The newly introduced RS-MC algorithm provides a substantial improvement in 
proton therapy dose calculation. The RS-MC algorithm was tested against 
measurements and G-MC simulations in both homogenous and heterogeneous media. 
In homogenous media, both the RS-PBA and RS-MC algorithms accurately predict the 
doses when no range shifter device is used. However, when a range shifter is used, 
dose discrepancies of up to 8% are observed at shallow depths (< 1 cm) between 
measured and RS-PBA for an air gap of 31.5 cm. This discrepancy has been attributed 
to the lack of proper handling of secondary protons (nuclear halo) created in the range 
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shifter as they are transported over the air gap into the patient. In the RS-PBA 
algorithm, secondary protons created by non-elastic nuclear scattering are taken into 
account by a second Gaussian in the proton fluence function, as for example described 
by Suokup et al. (23). The size and relative weight of this secondary Gaussian is a 
function of initial beam energy and WET of the calculation point. This implies that the 
algorithm does not handle inhomogeneities along the beam path. Since the range 
shifter is treated as an extension of the patient in the RS-PBA algorithm, there can be a 
substantial inhomogeneity created by the air gap between the range shifter and the 
patient outline. The angular distribution of the secondary protons is rather wide, with the 
consequence that they will spread far away from the central beam axis as they move 
over the air gap. Since this effect is not considered by the ad hoc treatment of the 
nuclear halo, the dose in the entrance region will be overestimated by the RS-PBA 
algorithm. Secondary protons with higher energies will be more forward directed, and 
the error becomes smaller and smaller deeper into the patient. This is clinically 
significant for sites like breast where the target extends to the surface thus requiring a 
7.5 cm WET range shifter for treatment planning. Due to the extent of the target 
volume, the largest snout (40 cm x 30 cm) is often required for treatment planning. This 
necessitates the air gap between patient and range shifter to be large (>10 cm) to avoid 
collisions. At our institution utilizing the RS-PBA algorithm, the measured doses are 
indeed often lower than the planning doses for such beam configurations, thus requiring 
additional intervention during treatment planning such as scaling up of monitor units. 
Utilizing RS-MC algorithm for such cases will provide accurate doses and also improve 
the workflow.  
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We also observed superior performance from the RS-MC algorithm in predicting 
doses when oblique beam angles are used in combination with a range shifter. For our 
test in a water phantom, with an oblique beam incident at 45 degrees, the RS-PBA 
algorithm showed broadening in distal-fall off. When an oblique beam with a range 
shifter is incident on the phantom, the dose discrepancy at shallow depths can be 
attributed to the limitation of the analytical algorithm to model range shifter and air gap 
as described in the paragraph above. The broadening of the distal edge can be 
attributed to the way that each spot is discretized into several algorithmic pencil-beam 
ray traces, so-called sub-spots. In RS6, this discretization into sub-spots is done at the 
entrance plane of the range shifter. As the sub-spots are transported through the range 
shifter and over the air gap, they may become significantly large at the patient surface 
and star to overlap each other. Since each sub-spot will see the patient as a sequence 
of semi-infinite layers, stacked perpendicular to the central axis, an inclined surface will 
not be correctly modeled by the sub-spots. The error will increase with the size of the 
sub-spots, and thereby with the magnitude of the air-gap. In RayStation 6 Service Pack 
1 (RS6 SP1 released in April 2017), the discretization of the spots into sub-spots has 
been updated when a range shifter is used. Instead of performing the sub-spot 
discretization at the range shifter entrance plane, it is now done at the patient surface in 
the same manner as is done when no range shifter is present. The range shifter and 
air-gap is considered by first transporting the phase-space of the Gaussian spots 
without discretization (so-called single tracing), a handling that is motivated by the fact 
that a range shifter is a laterally homogenous device. To investigate the impact on the 
distal penumbra of this more efficient discretization, we have re-calculated the depth 
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dose of the inclined SOBP2 beam using PBA algorithm of RS6 SP1 (RS-PBA-SP1). 
The result is compared to the corresponding central axis doses of RS-PBA, RS-MC, 
and measurement in Figure 38, which clearly demonstrates that the new algorithm is a 
substantial improvement as compared to the previous one with respect to the distal fall 
off. The (80-20%) distal fall-off of the RS-PBA-SP1 dose curve is 10.0 mm, 
corresponding to an error relative the measured distal fall-off of 1.2 mm. This value 
should be compared to the RS-PBA distal fall-off error of 5.1 mm. In fact, this value is 
even better than the error of the G-MC (-1.7 mm), although RS-MC is still best at -0.8 
mm (see Table 9).  
Having accurate representation of distal penumbra is very important for optimal 
treatment planning. Quite often in proton therapy, there are critical structures near the 
distal edge where accurate dose estimation is paramount. Generally, sites like H&N, 
brain, and breast require oblique beams and the use of a range shifter, with spinal cord, 
brainstem, and lung structures that may located at or after distal edge. Using RS-PBA 
algorithm for such cases, the planner may compromise target coverage to meet the 
critical structure doses. Although RS-PBA-SP1 is an improvement in terms of distal-fall 
off for oblique beams employing a range shifter, it is still recommended to use RS-MC 
for such cases, since the problem with the surface dose is still unsolved. 
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Figure 17. Demonstration of improved distal fall-off modeling in RS-PBA- SP1. SOBP2 
at the central axis with a range shifter of 7.5 cm WET is plotted for RS-MC (solid green 
line), RS-PBA (solid blue line), measurement (red square), and RS-PBA-SP1 (dotted 
black). The beam was incident at 45 degrees on a water phantom. 
 
  RS-MC also outperformed RS-PBA in phantom with simple slab 
inhomogeneities. For both lung and bone slabs, RS-MC accurately predicted the dose 
profile due to inhomogeneity verified by measurements and G-MC simulations. RS-PBA 
showed local dose errors of as much as 50% for doses >20% of the maximum at the 
distal edge interface. The differences in doses by RS-PBA algorithm is again due to the 
infinite slab approximation. For protons at the bone (or lung) and water interface, a 
proton pencil beam that is traversing through bone may be partially in water and vice 
versa. When many neighboring pencil beams are considered together, this has an 
impact of broadening in the distal fall-off as seen in figure 35. For sites like H&N, brain, 
and lung, one could expect complex anatomic interfaces between sinus cavities, bone, 
and soft tissue resulting in inaccurate doses reported by RS-PBA. In an 
anthropomorphic phantom test, RS-MC algorithm was found to accurately predict the 
fine features of the isodose lines due to lateral inhomogeneities for all the measurement 
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planes. The RS-PBA algorithm often displayed highly uniform doses for planes towards 
the distal edge, without properly accounting for lateral variation in tissue density.  
One of the concerns with MC-based dose calculation engines is the calculation speed. 
For a commercial dose calculation algorithm to be used for routine use, its performance 
should be similar to current analytical algorithms. We performed a simple comparison 
for a few relevant clinical cases to provide an estimate of the speed and performance. 
We calculated the doses for sites like breast, brain, H&N, lung, prostate (with pelvic 
nodes) with both RS-PBA and RS-MC calculation algorithms (table 12). The MC plans 
were calculated with 1% and 2% statistical uncertainty. The plans were previously 
optimized using the RS-PBA algorithm. Out of six scenarios evaluated, RS-MC was 
able to calculate doses faster than RS-PBA for three sites using 2% statistical 
uncertainty. For all six scenarios, calculation times for RS-PBA and RS-MC were within 
20 seconds of each other. If 1% statistical calculation accuracy is desired, RS-MC was 
always slower and could take as much as 4 times the dose calculation time of RS-PBA 
e.g., for a brain case the time of calculation increased from 10 seconds for RS-PBA to 
42 seconds for RS-MC. We found calculation speed of RS-MC algorithm to be 
adequate for routine clinical use at 2% statistical uncertainty. 
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Table 12. Comparison of calculation times for six different plans between RS-PBA and 
RS-MC. The plans were previously optimized using the RS-PBA algorithm.  
 
 
 
The recent surge in number of proton centers worldwide is due in large part to 
advantages in proton physical depth dose characteristics that reduce the integral dose 
to healthy tissue for fixed tumor dose as compared to conventional x-ray therapy. A 
number of clinical trials (69-72) are underway comparing the long term survival and 
normal tissue toxicities between proton and photons. While the commercial dose 
calculation offerings in photons have improved considerably in last decade, not much 
progress has been made for proton dose calculations beyond mainstay analytical pencil 
beam algorithms. Our investigation has shown the need to implement MC dose 
calculations methods for proton spot scanning. Use of analytical algorithms may lead to 
findings that may show proton radiotherapy as unfavorable for certain disease sites as 
the magnitude of dose errors (~5 to 50%) is significant.  
Several assumptions and limitations of our investigation should be noted. 
Although, we tested RS-MC for a variety of test cases, not every scenario can be 
simulated. The comparison between G-MC and RS-MC was performed for test cases in 
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water and simple slab heterogeneities. We did not evaluate any cases with implanted 
high density markers or surgical clips that are encountered so frequently in proton 
therapy. For dose measurements in oblique beam, a MatrixxPT device was utilized. The 
angular dependence of MatrixxPT has not been investigated in the literature. For G-MC 
beam model, an Ionization potential of 75 electron volts for water was used. The recent 
ICRU Report 90 (2016) has updated this value to 78 electron volts, which should 
change the range of proton beam in water. In our investigation, the maximum range 
error was 1 mm and average 0.3 mm. As our measured ranges matched well with 
simulated, the updated value of ionization potential should not impact the results 
reported in this manuscript. We believe that despite of these limitations, our 
investigation provides valuable information pertaining to validation of a commercial 
Monte Carlo dose calculation algorithm that will be beneficial to proton therapy 
community. 
3.5. Conclusions 
In this investigation, we performed a comprehensive evaluation of a newly 
available commercial Monte Carlo dose calculation algorithm, RS-MC, for use in proton 
spot scanning. The performance of RS-MC was tested against measurements and G-
MC simulations in a variety of homogenous and heterogeneous phantom conditions. 
Both RS-PBA and RS-MC algorithms were found to be suitable for dose calculation in 
water phantoms with normal incidence of beam and small air gaps with range shifters. 
However the accuracy of RS-PBA was found to be clinically unacceptable when a 
range shifter is employed with oblique beams, large air gaps, and/or heterogeneous 
media. RS-MC provided superior performance for all these scenarios and should be 
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integrated into routine clinical use. Furthermore, the dose calculation speed of RS-MC 
algorithm is similar to RS-PBA at 2% statistical uncertainty.  
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CHAPTER 4 EVALUATION OF CERAMIC MARKER FOR THE 
TREATMENT OF OCULAR MELANOMA WITH PROTON THERAPY 
 
4.1. Introduction 
Although rare, ocular melanoma is the second most prevalent type of melanoma 
after skin and accounts for about 3.7% of all melanomas (73). It is the most common 
primary cancer of the eye in adults that arises in the iris, ciliary body or choroid. The 
current treatment options include surgical enucleation, trans pupillary thermotherapy, 
cryotherapy, proton therapy, brachytherapy, and stereotactic radiosurgery (74). The 
goals of the treatment are to prevent further growth of the tumor, preserve vision, and 
reduce the risk of metastases. 
Proton therapy has been used for treatment of ocular melanoma since 1975 (75) 
with excellent control rates of 73% to 99% (76-80). Utilization of proton therapy for 
ocular melanoma offers a reduction of integral dose to preserve more healthy tissue 
around the target and mitigate risk of potential side effects. Due to the small size of 
ocular tumor volumes, a high degree of accuracy is required for imaging and 
positioning. Generally this is achieved through the use of implanted markers that are 
easily visualized through x-ray imaging. The markers are inserted in the vicinity of the 
target volume and are used for daily image-guided radiation therapy (IGRT). An ideal 
marker is the one that is readily visible on kV radiographs, produces minimal artifacts 
on the CT images, and causes no dose shadow in the underlying tissue (81). However, 
in order to provide good the visibility on kV radiographs, the markers have to be made 
either of high density material (high atomic number) or physically thick. Both of these 
have potential to cause substantial dose attenuation behind the marker. For proton 
therapy, the presence of the marker in the beam path not only causes changes to the 
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depth-dose but also changes to the proton beam range, resulting in under-dosing of 
target that lies distal to the marker. However, fiducial marker based alignment is very 
common in proton therapy for prostate (81-83), liver (84,85), and ocular treatments (86-
89). Much effort from vendors has gone in developing markers that are as close to ideal 
marker as possible. Fiducial markers come in different configurations and some of the 
most common materials are gold, stainless steel, tantalum, and carbon coated with 
ceramic core (zirconium oxide). The most common shapes are wire-coil, rod, spherical, 
star-shaped, and dumbbell (90).  
  Tantalum markers (Mira Inc., Uxbridge MA) have been used extensively (89-91) 
for alignment of ocular melanomas for more than 25 years. These markers form a 
circular disc measuring 2.5 mm wide and 0.17 mm thick and are made of tantalum 
(atomic number 73, and density 16.4 g/cc). In addition to the extensive CT image 
artifacts, these markers have also shown to cause substantial dose shadows. 
Newhauser et al (89) performed Monte Carlo simulations and film measurements to 
conclude that dose attenuation is a function of orientation and depth of the marker in 
the proton beam. For the clinically relevant case, where the marker is aligned 
perpendicular to the beam, dose attenuation of up to 26% was seen. Ptaszkiewicz (91) 
performed two dimensional dose measurements using the thermoluminesecent 
dosimetric system and showed under-dosing behind the marker from 4 to 32%. Both 
investigations recommended comprehensive considerations in marker placement and 
treatment planning by the ophthalmologist, medical physicist and radiation oncologist.  
However, due to the requirement of 3-4 markers near ocular target volumes for 
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accurate image alignment, there is often a compromise in the selection of less 
dosimetrically ideal beam angles in order to avoid delivery through markers. 
Recently, a new fiducial marker developed by Carbon Medical Technologies has 
been introduced in the market with potential usage for ocular target alignment. The 
marker is made of relatively low atomic number  ceramic substrate (zirconium oxide-
density 5.68 g/cc) and has promise to reduce the CT imaging artifact as well as the 
dose shadow while still maintaining the x-ray visibility. The objective of this study is to 
estimate the dosimetric impact and present a management strategy when the fiducial 
marker is placed in the field for ocular melanoma treatments. The performance of the 
marker for daily IGRT is also evaluated. The measurements and MC simulations were 
done based on the framework derived from a similar study done by Newhauser (89) for 
the tantalum marker. A comparison between tantalum and this new fiducial marker is 
also discussed. 
4.2. Methods and Materials  
4.2.1. Measurements 
The BioMarc SecureTM fiducial marker (Carbon Medical Technologies, St Paul, 
MN) is a newly available marker that is composed of a ceramic core (zirconium oxide) 
and pyrolytic carbon coating. According to the manufacturer, the carbon coating 
provides enhanced biocompatibility for the permanent placement of markers.  The 
combination of core material and carbon coating makes the marker compatible for all 
forms of radiation therapy and imaging (CT, MRI and Portal). The marker dimensions 
as well as composition information were obtained from the manufacturer. The marker is 
a dumbbell shaped (Figure 39) with a length of 4.62 mm, width of 1.65 mm (at the 
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widest part), and thickness of 0.66 mm. The dumbbell shape makes the marker easier 
to visualize in x-ray images and prevents the migration of the marker in the tissue. It 
also allows the holes at the ends to be used for suturing purposes. 
 
Figure 39. Enlarged view of BioMarc Secure fiducial marker. 
 
The marker was placed inside an Alderson Rando head phantom (Radiology 
Support Devices, California, US) roughly near the orbit region. The head phantom was 
positioned at isocenter and kV x-ray images were taken in one of the treatment rooms 
at SCCA-PT center. Both the flat x-ray panel and x-ray tube are installed and 
maintained by the IBA (Ion Beam Applications, Louvain-Neuve, Belgium). The images 
were obtained using the pre-programmed head anterior-posterior (AP, peak kV= 85, 
mA= 400, and mS=320, SID= 200 cm) and head right-left lateral (LAT, peak kV= 85, 
mA= 320, and mS=250, SID = 200 cm) protocols in the Verisuite (MedCom GMBH, 
Darmstadt, Germany) imaging software. The images were qualitatively analyzed to see 
if the markers are clearly distinguishable from the normal anatomy. In addition to the 
planar x-ray images, computed tomography (CT) images were also obtained using the 
GE Optima CT580 scanner (GE Healthcare, Waukesha, WI). The protocol was typical 
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of adult ocular images (peak kV= 120, Slice thickness= 0.625 mm). Qualitative 
evaluation of CT images was performed to see presence or absence of any artifacts. 
 
Figure 40.  Experimental set up for marker dose shadow measurements. The marker 
(C) was embedded into a 0.5 cm thick Styrofoam slab (B) that was sandwiched in solid 
water phantom (A and D). The upstream solid water (A) was 7 cm thick. The marker 
was placed in three different orientations: perpendicular (C1), parallel (C2), and 
transverse (C3).  
 
For dose shadow measurements, an in house phantom consisting of slabs of 
solid water and Styrofoam (density= 0.021 g/cc, Owens Corning Foam Insulation, 
Toledo, OH) was created (Figure 40). The marker was inserted into the Styrofoam slab 
in three cardinal orientations with respect to proton beam: (i) parallel, (ii) perpendicular, 
and (iii) transverse. Gafchromic EBT3 film (Ashland Inc., NJ) was placed at many 
depths after the marker to measure the dose shadow. In order to ensure the 
consistency of geometry, the films were always placed at the same depths for 
measurement with different orientations of the marker and un-perturbed measurement 
without marker. 
92 
 
 
 
The dose shadow measurements were carried out in a proton beam gantry at the 
SCCA-PT center. The beam line is an IBA PBS system with available energies of 98.5-
226 MeV and corresponding ranges in water 7.5-32 cm. For shallow targets 
encountered for ocular lesions, a proton range of 2- 5 cm in water is required. In order 
to use our current pencil beam system for ocular treatments, a range shifter device 
(Shen et al., 2015) needs to be used. A range shifter is a material of uniform thickness 
that when placed in the proton beam has the impact of pulling the range back thus 
enabling the treatment of shallow depth targets. A single layer proton beam 
corresponding to range 8.5 cm and field size 3 x 3 cm2 was used for measurements. A 
proton beam of 8.5 cm range with a 4 cm water equivalent thickness (WET) range 
shifter effectively provides a 4.5 cm range typical of what is used for ocular treatments. 
The single layer beam has spots placed in rectilinear fashion with 2.5 mm spot spacing 
thus resulting in total of 169 spots.  
EBT3 film was exposed to approximately 28.5 Gy at the depth of maximum dose 
using the single layer beam. Four measurements corresponding to three marker 
orientations and one measurement without a marker were made. The films were 
scanned 48 hours after the exposure on a flatbed scanner (Epson Expression 
11000XL, Epson America Inc., California, USA) using 300 pixels per inch of resolution 
and landscape orientation. The digitized films were analyzed using the commercially 
available DoseLab software (Mobius Medical Systems, TX, US). A control film that was 
similarly handled but not exposed was also scanned to obtain net optical density. 
Gafchromic film has been shown to be highly energy dependent (92-96) with increasing 
under-response as the point of measurement moves closer to the Bragg peak. This is 
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also called the quenching effect and needs to be taken into account for accurate 
dosimetry.  Reinhardt et al (94), found under-response of as much as 20% for the 
lowest measured residual energy of 4 MeV corresponding to a 200 MeV incident proton 
beam. Fiorini et al (92), showed for proton energies encountered in eye treatments, 
under-response can be expected to reach as much as 50% in the low energy region 
(distal edge). Therefore, energy response correction is critical for using EBT3 films for 
proton therapy. We corrected for the energy response by making diamond detector 
(described below) and EBT3 film measurements in the unperturbed (without marker) 
beam. These measurements were made using the same single layer beam (range=8.5 
cm) that is used for marker evaluation. The optical density from EBT3 films was 
correlated to the known doses measured by the diamond detector to derive correction 
factors as a function of depth in the proton beam.  
The depth-dose was also measured without the marker using the commercially 
available microDiamond detector (Type 60019, PTW-Freiburg, Germany). Goma et al 
(67) have shown that the microDiamond detector’s response is independent of the 
dose-rate and proton beam energy. Due to its small size and tissue equivalency, the 
microDiamond detector introduces a minimal amount of perturbation and is ideal for 
making proton depth-dose measurement (97). The microDiamond detector was 
mounted inside a homemade one dimensional water tank and connected to a PC 
electrometer (Sun Nuclear Corp., Melbourne, FL). Integrating charge measurements for 
the whole beam delivery were made at many points along the depth-dose with finer 
resolution in the high gradient region. 
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4.2.2. MC Simulations 
MC simulations for the marker shadow were performed using the open source 
package Geant4 Application for Tomographic Emission (GATE) (40). GATE 
encapsulates the Geant4 libraries to provide a script based environment to run particle 
simulations. Grevillot et al (63) provided investigations of the different GEANT4 settings 
for proton particle therapy energy range. As recommended, the range cut (production 
threshold for secondary particles after EM interactions) and maximum allowable step 
size value (distance to next interaction) were set to 0.1 mm. The pre-calculated EM 
tables for mean free path, restricted stopping power, and range were set to 20 bins per 
decade to accurately describe the EM interactions.  The physics models were 
implemented using the pre-defined physics builder mechanism and included binary 
cascade along with option 4 for electromagnetic interactions. The ionization potential for 
water, important for accurate range modeling, was set to 75 electron volts based on the 
recommendations of ICRU reports 37 (64) and 49 (8). The voxel size was set to 0.2 mm 
in -x, -y, and -z directions.   
The first simulation was performed of the unperturbed single layer pristine Bragg 
peak in water for a range of 8.5 cm, and field size of 3 X 3 cm2.  The geometry was set 
up to be similar to the microDiamond depth-dose measurement. The dose was tallied in 
the x-z direction along the beam central axis.  A beam model corresponding to the 
gantry delivery system at SCCA-PT was implemented based on the recommendation 
by Grevillot  et al (62).  The PBS beam model is entirely based on the measurements 
after the nozzle exit with source simulated at 40 cm upstream from the isocenter. 
Lateral spot profile measurements at 5 different planes along with integrated depth-
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dose measurements at the isocenter plane were made to fit the GATE/GEANT4 model. 
The full validation of the model is presented in Chapter 3. For the purpose of this 
exercise, the agreement between pristine Bragg peak measurements versus simulation 
has been shown (Figure 42). 
The second set of simulations was done to evaluate the shadow due to the 
marker in all three cardinal orientations. The simulation geometry was the same as the 
measurement geometry (Figure 40). For the simulation with the marker in the parallel 
orientation, a rotation of 8.5 degrees was applied to the marker to match the 
measurement geometry.  
A final simulation was performed with beam conditions identical to realistic 
clinical plans. A typical clinical beam is range 3 cm and SOBP width 1.5 cm. In our PBS 
system, this beam can be created using the range 9 cm, SOBP width 1.5 cm in 
conjunction with a range shifter of 6 cm WET. For the purpose of this simulation, the air 
gap between the range shifter and water phantom was assumed to be zero, and 
Styrofoam slab was removed from geometry. The effect of marker depth as well as 
orientation with the SOBP region was evaluated.  
All the simulations were performed on commercial a MacBook Pro (Apple Inc., 
Cupertino, CA) laptop computer with 2.2 GHz quad-core Intel Core i7 processor, 16 GB 
of 1600 MHz DDR3L onboard RAM running the OS X Yosemite version 10.10.4 
operating system.  
4.3. Results 
The marker showed excellent visibility on the planar x-ray images for both AP 
and LAT views (Figure 41). These images suggest that these markers are suitable for 
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ocular target localizations. The CT images of the phantom showed the presence of 
black and white streaks that are typical of high atomic number materials (Figure 41). 
 
Figure 41.  Planar x-ray images and an axial CT slice with BioMarc secure marker. The 
marker could easily be seen on the x-ray images. Streak artifacts due to marker were 
seen on the CT images. 
 
The unperturbed depth-dose measured with the microDiamond detector and the 
MC generated curves are shown in Figure 42. The maximum difference was found to 
be 3.8% at 8.5 cm depth. The relative good agreement between MC and measurement 
confirmed that the gantry beam was accurately modeled in GATE/GEANT4.  
 
Figure 42. A single layer unperturbed (solid black line) beam with 8.5 cm range was 
simulated in GATE/GEANT4. The measurement (red filled circles) of the same beam 
was performed in water tank using the microDiamond detector. The point-by-point 
difference (blue open diamonds) between the simulated and measured depth-doses is 
shown on right axis.  
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Figure 43.: Qualitative results of the dose shadows for three marker orientations.  The 
marker is placed at 7 cm depth with dose shadows shown for 7.6 and 9.1 cm depths. 
All depths are given in water equivalent thicknesses. The images were enhanced for 
contrast for better visualization. The pixel size is 0.2 X 0.2 mm2 for MC images, and 300 
dots per inch for film images.  
 
Figure 44. GATE/GEANT MC generated two dimensional depth-dose maps with 
marker oriented in perpendicular (A), transverse (B), and parallel (C) directions. The 
markers are placed inside the 0.5 cm Styrofoam (D) block placed at the 7 cm water 
equivalent depth.  
 
98 
 
 
 
 
Figure 45. Comparison of MC simulated depth-dose distributions and EBT3 
Gafchromic film measurements. MC simulations are shown for (A) unperturbed depth 
dose without any marker, (B) marker oriented in transverse direction, (C) marker 
oriented in perpendicular direction, and (D) marker oriented in parallel direction. Top 
Panel (i) shows depth dose in entirety. Bottom panel (ii) shows depth dose between 7 to 
9 cm for better clarity. The measurement using the EBT3 Gafchromic film are shown for 
clip orientations: transverse (open triangles), perpendicular (open diamonds), and 
parallel (open circles). Also shown is the measurement of the unperturbed depth-dose 
using the EBT3 film (open squares). 
 
The single layer marker shadow measurements using the EBT3 film and 
simulations using MC showed substantial dose shadows at the central axis of the 
marker. The qualitative characteristics of the dose shadows produced by the MC and 
EBT3 film at water equivalent depths of 7.6 and 9.1 cm are shown in Figure 43. Figure 
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44-45 shows the depth-dose characteristics for all three marker orientations. The dose 
shadows produced due to the markers were substantially worse for the parallel 
orientation compared to the other two orientations. In the high dose region from 8 to 8.3 
cm, the dose attenuation of up to 29 to 38% was seen for the marker in the parallel 
orientation. Since the active length of the marker is ~4.6 mm, the approximate water 
equivalent thickness in worst case of parallel orientation is a product of active length 
and physical density (5.68 g/cc) ~26 mm. Therefore for the 8.5 cm range beam, the 
marker is able to block the primary protons completely when positioned at the 7 cm 
WET depth. For perpendicular and transverse orientations, there is enhancement of 
dose immediately after the marker, as the proton beam is pulled back due to the higher 
density of the marker. A dose enhancement of up to 18 to 23% was seen for transverse 
orientation within 4 mm past the marker. In the distal edge region from 8.5 to 8.8 cm, 
dose attenuation from -11 to -45% was found for all three configurations. In addition to 
the dose attenuation, proton beam penetration, measured by the distal 50% of the 
unperturbed beam, was also reduced by 1.1, 0.7, and 0.9 mm for parallel, 
perpendicular, and transverse orientations respectively. The agreement between the 
EBT3 film and MC is shown in Table 13. Differences of up to ~10% were noted. The 
differences were attributed to the small amount of misalignment in positioning of the 
marker in the beam path and up to ~4% differences that were seen between pristine 
peak measurement using microdiamond detector and MC simulation. 
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Figure 46. Monte-Carlo simulated dose shadows behind the marker for a typical clinical 
SOBP beam. Three orientations of the marker were simulated. Impact on dose shadow 
due to depth of marker within the SOBP was studied by placing marker at either 
proximal or distal side of the SOBP. 
 
 
Figure 47. One dimensional depth-dose through the central axis of the marker 
corresponding to the 2-D dose map shown in figure 46 for the marker placed at the (i) 
proximal and (ii) distal side of the SOBP. Shown are depth-dose without marker i.e. 
unperturbed (solid red line), and marker in transverse (orange dotted line), 
perpendicular (blue dotted line), and parallel (purple dotted line) orientations. 
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Table 13. Depth dose differences between MC simulations and EBT3 film 
measurements. Results are shown for all three fiducial orientations. 
 
Lastly, the results of the dose shadows due to the marker in the clinically 
relevant SOBP beam are shown (Figures 46 and 47). A total of six combinations were 
simulated: 3 cardinal orientations at two depths. The two depths corresponded to the 
possibility of marker placed in the SOBP after the proximal rise and just before the 
distal drop. As expected the dose shadows are larger when the marker is placed 
towards the distal part of the SOBP as the residual range of the proton beam is smaller. 
In addition, the dose shadows are worse for the parallel orientation as it presents the 
longest path for proton beam to travel inside the marker. However, the parallel 
orientation is also the least likely to occur clinically. In addition, parallel orientation also 
shields a smaller volume of tissue underneath the marker. The amount of dose 
attenuation for parallel orientation ranged from 23 to 56% when the marker is placed 
near proximal side of the SOBP. Here, the percentage attenuation is expressed with 
respect to unperturbed dose at the same location. For parallel orientation at distal part 
of the SOBP, the maximum dose attenuation was 89% immediately behind the marker. 
In this case, the low energy protons are completely stopping in the marker and the dose 
is entirely made up of scattered protons not interacting in the marker. For perpendicular 
and transverse orientations near the distal edge, the proton beam still has residual 
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range that is larger than the path length encountered in the marker. Therefore, the end 
result is that of pulling back the proton range that could result in the loss of coverage at 
the distal side of the target; the dose attenuation of up to 61% were seen towards the 
distal side of the SOBP for both cases. The D50% (depth of 50% dose level) ranges 
were pulled back by 2 and 2.4 mm for perpendicular and transverse orientations 
respectively. The size of dose shadows behind the marker was also found to be a 
function of orientation. Immediately behind the marker, the size of the dose shadow 
was as large as the effective area presented by the marker in the incident beam 
direction. While the amount of dose attenuation was largest for the marker oriented in 
parallel direction, the volume shielded was smallest. There is further reduction in 
volume shielded downstream as dose from scattered protons starts to build up. 
4.4. Discussion 
As the number of proton centers increases, more and more institutions will 
implement ocular therapy programs. One of the considerations for ocular therapy is the 
selection of a suitable marker for daily IGRT. Tantalum markers have been used for 
>25 years but introduce substantial streak artifacts on CT and large dose shadows (89). 
During our search for a suitable marker that could alleviate some of the issues of the 
tantalum marker, the carbon coated ceramic core BioMarc Secure was offered as an 
alternative by the manufacturer for ocular IGRT. In terms of size, the tantalum marker is 
a circular disc shaped that is 2.5 mm wide and only 0.17 mm thick. In contrast the 
Biomarc Secure is a dumbbell shaped and roughly 4.6 mm long and 0.66 mm thick. 
Therefore, the tantalum marker provides a markedly smaller footprint that may be 
easier for both ophthalmologist to suture and patients to tolerate. In terms of the 
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visibility on kV x-rays, operator was able to localize both markers on orthogonal images. 
Both markers produced streak artifacts in the CT images. Both markers produced 
significant dose attenuation in the underlying media. In the transverse orientation, the 
BioMarc Secure produced up to 40% dose shadows. Similarly, the parallel orientation of 
tantalum maker produced up to 26% dose reduction (89). One would theoretically 
expect reduced dose shadows from the BioMarc Secure marker due to low atomic 
number and density. However, the dosimetric benefits from lower density are offset by 
the increase in the thickness of the marker. If we assume that the most probable 
orientation for tantalum marker in the beam path is parallel and BioMarc Secure is 
transverse, the effective area as seen by the incident proton beam is roughly 3.8 and 
4.9 mm2 for tantalum and Biomarc markers respectively. Therefore, the new Biomarc 
marker shields a greater volume underneath the marker. Due to its bigger physical size, 
greater dose shadows and effective shielded volume, the BioMarc Secure marker does 
not present any improvements over tantalum marker.  
In radiation therapy, ionization chambers are considered the gold standard for 
accurate dose measurements. However, using ionization chambers for measuring the 
dose shadow behind the marker is not feasible due to the small size of the marker and 
the resolution of the ion chamber. Film measurements provide greater resolution but 
suffer from linear energy dependent (LET) response (92, 95, 96) that introduces 
additional uncertainty. In our study, the measurement using the diamond detector was 
used to correct the film response, and agreement within ~10% was achieved between 
film and MC simulations. MC simulations provide a flexible platform to investigate the 
dose attenuation due to markers. MC methods enable users to simulate accurate 
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geometries and beam configurations that cannot be reproduced in the measurements. 
Furthermore, the doses can be calculated in sub-millimeter resolution, something that 
cannot be achieved in commercial treatment planning systems. 
At SCCA-PT, ocular melanoma treatments are given most frequently in 5 
fractions using 1-2 beams. By using multiple fractions, some averaging of the dose 
shadow should occur due to random errors introduced in the daily IGRT. This has the 
potential to reduce the severity of dose attenuation. Furthermore, having more beams 
should also alleviate the clinical impact of dose shadows. Based on our study, we do 
not recommend treating with a single beam and Biomarc marker in the beam path, as 
this scenario could result in severe under-dosing of a very small volume behind the 
marker. In the event that the marker must be present in the beam path, it is preferable 
for the marker to reside on the proximal side of the SOBP with added range to 
compensate for the pull back. 
Several assumptions and limitations of our investigation should be noted. The 
marker is a zirconium oxide substrate with a 0.05 mm pyrolytic carbon coating. For our 
MC simulations, we ignored the coating and assumed the whole marker to be one 
material.  In addition, all of the sharp edges have been removed by the process of 
chamfering. This was also ignored and not implemented for simulations. We believe 
these assumptions to be minor and do not expect any changes to our conclusions.  
4.5. Conclusions 
Evaluation of the recently available carbon coated BioMarc SecureTM marker was 
reported for application to IGRT of ocular melanoma. The marker was readily visible on 
the planar kV x-rays. On CT scans, metal artifacts in the form of black and white 
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streaks were visible. The dose attenuation behind the marker was assessed using the 
MC methods and gafchromic dosimetry. As expected, the dose attenuation was found 
to be a function of marker orientation and position within the SOBP. For clinically 
relevant beams, dose attenuation of up to 89% was found for the worst case position of 
the marker within the beam. There is also a range pull-back effect for protons passing 
through the marker leading to severe under-dosing of the target at the distal end of the 
SOBP. It is recommended that all these factors be duly considered if BioMarc Secure 
marker is used for ocular treatments. 
In addition, a comparison of BioMarc Secure with tantalum marker was 
presented. It was found that due to its larger physical size, greater dose shadows, and 
larger effective shielded volume, BioMarc Secure marker may be less attractive for 
ocular melanoma compared to widely used tantalum marker. 
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Chapter 5 Summary of Findings 
Information provided by the TPS plays a pivotal role in radiation therapy by 
directly impacting patient care. Clinicians evaluate the dose distributions provided by 
the TPS to balance the risk of side effects against the treatment of a tumor. It is 
therefore imperative that a TPS provides accurate information to the planner. The 
quality of the output dose distributions generated by the TPS is dependent mainly on 
two factors: (i) quality of beam data obtained through measurements that is used an 
input for beam modeling, and (ii) inherent dose calculation accuracy of TPS. The 
commissioning of the TPS is a major undertaking that involves beam data 
measurement, beam modeling, and beam validation. Uncertainties and errors in any of 
the commissioning steps can lead to inaccuracies in the output dose distributions and 
have a potential to impact patient treatment outcomes. Generally, the input 
measurements are performed based on the recommendation by the TPS vendor. In 
addition, there are references in the form of AAPM or IAEA reports that can act as a 
resource for facilities to benchmark their TPS performance. However, unlike photon 
therapy, there are very limited literature and resources available for commissioning of 
proton therapy. To our knowledge, there are no AAPM reports with standards or 
tolerances that can be accessed to benchmark one’s beam data and evaluate the 
overall accuracy of the planning systems. 
The inherent accuracy of a TPS is dependent on whether the calculations are 
performed based on analytical methods or MC methods. Most of the current treatment 
planning is performed through pencil beam analytical methods in proton therapy. Until 
recently, there was no commercial MC dose calculation algorithm available that could 
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be used clinically. However, calculations using the MC have been performed for proton 
therapy for more than 20 years, albeit only for research purposes using one of the 
multi-purpose MC codes such as MCNPx and Geant4. However, these codes are not 
suitable for clinical use. With the recent introduction of commercial MC for dose proton 
spot scanning, one has the choice to calculate doses using either the analytical 
algorithm or MC. This brings up a couple of considerations: what kind of validation 
should be performed on MC before implementing it clinically, and what are the 
dosimetric differences in the performance of MC and analytical algorithms for clinically 
relevant conditions? 
This dissertation presents solutions to many of the issues highlighted above.  
The first objective of this research was to provide a framework of commissioning an 
analytical planning system based on manufacturer’s recommendations. The overall 
process of commissioning a planning system can be very daunting with limited time due 
to pressure of treating patients and non-familiarity with a new system. Chapter 2 
provides the reader with details of the commissioning and validation of a commercial 
analytical dose algorithm for proton spot scanning delivery. In order to reduce the 
number of measurements, the beam data was measured for 18 proton energies. The 
depth doses were measured with the largest pancake detector available at that time, 
i.e. an 8 cm Bragg peak chamber. The spot profiles were measured with a 2-D 
scintillator detector at many planes and off-axis distances. Several limitations of the 
planning system were found such as inability to accurately determine doses for larger 
field sizes (>15 cm) and larger energies (>218 MeV). As a part of final validation, test 
cases from AAPM TG-119 were planned and delivered. The gamma index for all the 
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planes tested using the 3% dose and 3 mm DTA tolerance ranged from 92.8 to 100%. 
The results of our commissioning and validation can serve as a guide and benchmark 
for many upcoming proton centers. 
The second goal of the study was to validate and benchmark a commercial MC 
dose calculation algorithm against measurements and simulations (chapter 3). A tertiary 
goal was to compare and contrast the performance of a pencil beam analytical 
algorithm against the MC algorithm. A beam model for the spot scanning gantry at the 
SCCA proton center was implemented in the GATE software package. The model was 
validated against measurements in a water phantom and was used for benchmarking 
the commercial MC algorithm. Validation was performed in a water phantom by 
measuring depth doses and profiles for three SOBP beams with normal incidence, a 
SOBP with oblique incidence, and a SOBP with a range shifter and large air gap. 
Further validation was performed against measurements and simulations in 
heterogeneous phantoms created by placing lung or bone slabs in a water phantom. 
Finally, MC and pencil beam analytical algorithms were compared to measured dose 
distributions in an Alderson-Rando phantom. As seen from the results, the MC 
algorithm showed highly accurate doses for most of the scenarios. In comparison, the 
pencil beam analytical algorithm was found to be insufficient when calculating doses 
with a large air gap, oblique beams, and anatomic sites with inhomogeneity. The pencil 
beam analytical algorithm showed up to a 10% difference in dose at the entrance for 
beams with range shifter and >30cm air gap while MC was always within 3% of the 
measurement.  For an oblique beam incident at 45 degree, the analytical algorithm 
showed up to 6% local dose differences and broadening of the distal penumbra by 5 
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mm. In an anthropomorphic phantom, it was found that the pencil beam analytical 
algorithm showed uniform doses and failed to show the impact of lateral 
inhomogeneities and fine features such as sinus cavities, bone, and soft tissue 
interfaces. The Monte Carlo algorithm demonstrated improved dosimetric accuracy over 
the analytical algorithm in the presence of homogenous, heterogeneous and 
anthropomorphic phantoms. The computational performance of RS-MC was similar to 
RS-PBA algorithm. For complex disease sites like breast, head and neck, and lung 
cancer, the RS-MC algorithm will provide significantly more accurate treatment 
planning. 
Finally, in Chapter 4, BioMarc SecureTM, a fiducial marker with ceramic core 
(zirconium oxide) and carbon coating, was evaluated for use in the localization and 
alignment of ocular melanoma targets using proton pencil beam scanning. An 
anthropomorphic phantom with implanted fiducial marker was scanned to obtain kV x-
ray and CT images. For dose shadow measurements, an in-house phantom was 
constructed using solid water, Styrofoam and EBT3 Gafchromic film. Dose attenuation 
behind the marker was measured at multiple depths and for three cardinal orientations: 
parallel, perpendicular, and transverse. MC simulations were set up to mimic the 
measurement geometry and dose attenuation behind the marker was studied for a 
single layer PBS beam. Qualitative analysis of the planar kV images showed excellent 
visibility of marker. Reconstruction artifacts in the form of light and dark streaks were 
present on the CT images. The film and MC simulations showed significant dose 
attenuation behind the marker that worsened when the marker was placed close to the 
distal edge. Dose shadows of up to 45% and range loss of up to 1.1 mm were seen 
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behind the marker. The transverse marker orientation in the clinical SOBP beam 
showed dose reduction of up to 61% and range pull-back of 2.4 mm. The dose 
attenuation was found to be a function of marker orientation and location within the 
SOBP. The analysis showed that small volumes behind the marker can receive severe 
under-dosing. This effect should be taken into account during the planning of treatment.  
 Proton Therapy, owing to its superior dose distributions, is emerging as a 
modality of choice for many radiation therapy treatments. It is anticipated that number 
of proton centers in the US and rest of the world will continue to grow at a fast pace for 
next few years. As new centers are opened, one of the most important considerations is 
the selection of a TPS. In this dissertation, we have provided methodology to 
commission a widely available TPS, RayStation, for proton spot scanning. The 
validation of both algorithms (pencil beam analytic and Monte Carlo) offered by 
RayStation is presented. We noted that pencil beam analytical algorithm has several 
shortcomings such as, inability to account for large air-gaps when range shifters are 
employed, inability to model oblique beams correctly, inability to account for 
heterogeneous anatomic features, and inability to correctly predict doses for large fields 
(>15cm) at greater depths (>20 cm). Our investigation concluded that RayStation’s 
Monte Carlo algorithm is able to predict doses accurately for all these scenarios and is 
computationally efficient to be used on routine basis.  
In this dissertation, a variety of phantom cases were used to demonstrate the 
improved accuracy of MC algorithm over analytical pencil beam algorithm. It is 
important to translate those improvements to actual patient cases and show the 
differences in dose distributions that are expected from using an improved dose 
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calculation algorithm. A number of abstracts (98-100) were recently submitted by our 
group to national and international meetings to highlight the importance of MC dose 
calculation in proton spot scanning. In a study by Fung et al. (98), retrospective analysis 
for three chest wall cases was performed comparing various dosimetric endpoints 
(Table 14). The plans were previously optimized using the pencil beam analytical 
algorithm to meet the target and critical structure dose constraints. The plans were then 
copied and re-calculated using the RayStation Monte Carlo dose algorithm. As can be 
seen in Table 14, for the three cases evaluated, there was a reduction in the PTV 
coverage (V95%: volume receiving 95% of prescription dose) by 11-29%. In addition, 
there was an increase in V20Gy and V5Gy (VxxGy= percentage of critical structure 
volume receiving xx Gy dose) for lung volumes. Overall, the MC re-calculated plans 
showed degradation in dose homogeneity as evident from increase in homogeneity 
index (HI).  
Table 14. Comparison of various dosimetric endpoints for three chest wall cases 
calculated using the RayStation pencil beam analytic algorithm and RayStation Monte 
Carlo algorithm. 
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In an another study by Maes et al. (100), a total of 10 lung cancer plans were 
retrospectively analyzed using the RayStation MC dose calculation algorithm. 
Evaluation of the V95 and HI of the CTV as well as V20Gy and VRX (Volume receiving 
prescription dose) for lung volume was performed. As shown in Table 15, there was a 
reduction in CTV coverage when plans were re-calculated using the RayStation MC 
dose calculation algorithm. There was also an increase in mean global hotspot from 
106% for PBA to 109% for MC. Although the studies outlined here cover only two 
anatomic sites and have a limited number of cases, these results in conjunction with the 
phantom analysis provided in this dissertation highlight the need to incorporate MC 
dose planning for proton spot scanning.  
Table 15. Comparison of various dosimetric endpoints for ten lung cancer cases 
calculated using the RayStation pencil beam analytic algorithm and RayStation Monte 
Carlo algorithm. 
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Purpose: Accurate dose calculation is one of the necessary components of radiation 
therapy. While the commercially available photon dose calculation algorithm offerings 
have improved considerably in the last decade, proton dose calculations are still 
performed using analytical dose calculation algorithms. The goal of this work is to 
validate a newly available commercial Monte Carlo (MC) dose calculation algorithm 
using measurements and simulations in Geant4 Applications for Emission Tomography 
(GATE) software. A secondary goal is to compare and contrast the performance of the 
pencil beam analytical algorithm against the MC algorithm. Finally, GATE simulations 
are used to evaluate a newly available ceramic marker for ocular melanoma proton 
therapy. 
Methods:  Analytical and MC beam models of a full 360 degree gantry at the Seattle 
Cancer Care Alliance proton therapy center were commissioned in the RayStation 
treatment planning system. Measurements were performed using a variety of detectors 
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such as parallel plate ion chambers, 2D ion chamber arrays, a Bragg peak chamber, a 
2D high resolution scintillation imager, and radiographic film. The analytical beam 
model was put through a series of tests that involved verification of point doses, PDDs, 
profiles, and doses in patient specific plans. The comparison of the analytical and 
RayStation MC (RS-MC) algorithms was carried out by measurements in homogenous, 
heterogeneous, and anthropomorphic phantoms.  For comparisons against simulations, 
a beam model was developed in the GATE MC Toolkit using the measured beam data.  
For evaluation of the ceramic marker, a custom phantom with styrofoam insert with an 
embedded marker was created. Simulations and measurements were made for the 
marker in parallel, perpendicular and transverse orientations relative to the beam. 
Results: For the analytical algorithm, evaluation of point doses in water showed dose 
differences>3% for proton ranges>30 cm, field sizes>15 x15 cm2, and depths>25 cm. 
When a range shifter was employed, the analytical algorithm showed dose 
discrepancies of up to 10% in the entrance region for air gaps>30 cm. In oblique beam 
conditions, the analytical algorithm showed broadening in the distal penumbra by up to 
5 mm.  The RS-MC algorithm matched measurements and GATE simulations to within 
3% at all points for SOBP depth doses, beams with a range shifter, and oblique 
incidence. The RS-MC also predicted accurate doses in an inhomogeneous phantom, 
where the simulations of the dose profile created at the interface matched 
measurements with 100% gamma index (GI) pass rate at 3% dose and 3 mm distance-
to-agreement (DTA). In an anthropomorphic phantom, 6/7 planes had GI> 90% using 
3% dose and 3 mm DTA for RS-MC. Corresponding numbers for the analytical 
algorithm showed only 3/7 planes with GI >90%. The ceramic marker showed 
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considerable dose attenuation behind the marker that worsened when the marker was 
placed close to the distal edge. The transverse marker orientation in the clinical SOBP 
beam showed dose reduction of up to 61% and range pull-back of 2.4 mm. 
Conclusions: The RS-MC algorithm demonstrated improved dosimetric accuracy over 
the analytical algorithm in the homogenous, heterogeneous and anthropomorphic 
phantoms. The computational performance of RS-MC was similar to the RS-PBA 
algorithm. For complex disease sites like breast, head and neck, and lung cancer, the 
RS-MC algorithm will provide significantly more accurate treatment planning. The dose 
attenuation behind the ceramic marker was found to be a function of marker orientation 
and location within the SOBP. The analysis showed that small volumes behind the 
marker can receive severe under-dosing. This effect should be taken into account 
during the treatment planning. 
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